<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Drug treatment for spinal muscular atrophy type I - Wadman, RI - 2019 | Cochrane Library</title> <meta content="Drug treatment for spinal muscular atrophy type I - Wadman, RI - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006281.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Drug treatment for spinal muscular atrophy type I - Wadman, RI - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006281.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006281.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Drug treatment for spinal muscular atrophy type I" name="citation_title"/> <meta content="Renske I Wadman" name="citation_author"/> <meta content="University Medical Center Utrecht, Brain Center Rudolf Magnus" name="citation_author_institution"/> <meta content="r.i.wadman@umcutrecht.nl" name="citation_author_email"/> <meta content="W Ludo van der Pol" name="citation_author"/> <meta content="University Medical Center Utrecht, Brain Center Rudolf Magnus" name="citation_author_institution"/> <meta content="Wendy MJ Bosboom" name="citation_author"/> <meta content="Onze Lieve Vrouwe Gasthuis locatie West" name="citation_author_institution"/> <meta content="Fay‐Lynn Asselman" name="citation_author"/> <meta content="University Medical Center Utrecht, Brain Center Rudolf Magnus" name="citation_author_institution"/> <meta content="Leonard H van den Berg" name="citation_author"/> <meta content="University Medical Center Utrecht, Brain Center Rudolf Magnus" name="citation_author_institution"/> <meta content="Susan T Iannaccone" name="citation_author"/> <meta content="University of Texas Southwestern Medical Center" name="citation_author_institution"/> <meta content="Alexander FJE Vrancken" name="citation_author"/> <meta content="University Medical Center Utrecht, Brain Center Rudolf Magnus" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD006281.pub5" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/12/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006281.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006281.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006281.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Neuroprotective Agents [*therapeutic use]; Oligonucleotides [*therapeutic use]; Randomized Controlled Trials as Topic; Spinal Muscular Atrophies of Childhood [*drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006281.pub5&amp;doi=10.1002/14651858.CD006281.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="WbpyPs9C";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006281\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006281\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006281\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006281\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa","ms","ja"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006281.pub5",title:"Drug treatment for spinal muscular atrophy type I",firstPublishedDate:"Dec 11, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neuromuscular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WbpyPs9C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006281.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006281.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006281.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006281.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006281.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006281.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006281.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006281.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006281.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006281.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6199 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006281.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/full#CD006281-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/full#CD006281-sec-0104"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/full#CD006281-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/full#CD006281-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/full#CD006281-sec-0037"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/full#CD006281-sec-0038"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/full#CD006281-sec-0063"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/full#CD006281-sec-0086"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/appendices#CD006281-sec-0109"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/table_n/CD006281StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/table_n/CD006281StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Drug treatment for spinal muscular atrophy type I</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/information#CD006281-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Renske I Wadman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/information#CD006281-cr-0003">W Ludo van der Pol</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/information#CD006281-cr-0004">Wendy MJ Bosboom</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/information#CD006281-cr-0005">Fay‐Lynn Asselman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/information#CD006281-cr-0006">Leonard H van den Berg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/information#CD006281-cr-0007">Susan T Iannaccone</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006281.pub5/information#CD006281-cr-0008">Alexander FJE Vrancken</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/information/en#CD006281-sec-0124">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 December 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006281.pub5">https://doi.org/10.1002/14651858.CD006281.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006281-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006281-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006281-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006281-abs-0002">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006281-abs-0001" lang="en"> <section id="CD006281-sec-0001"> <h3 class="title" id="CD006281-sec-0001">Background</h3> <p>Spinal muscular atrophy (SMA) is caused by a homozygous deletion of the survival motor neuron 1 (<i>SMN1</i> ) gene on chromosome 5, or a heterozygous deletion in combination with a point mutation in the second <i>SMN1</i> allele. This results in degeneration of anterior horn cells, which leads to progressive muscle weakness. By definition, children with SMA type I are never able to sit without support and usually die or become ventilator dependent before the age of two years. There have until very recently been no drug treatments to influence the course of SMA. We undertook this updated review to evaluate new evidence on emerging treatments for SMA type I. The review was first published in 2009 and previously updated in 2011. </p> </section> <section id="CD006281-sec-0002"> <h3 class="title" id="CD006281-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of any drug therapy designed to slow or arrest progression of spinal muscular atrophy (SMA) type I. </p> </section> <section id="CD006281-sec-0003"> <h3 class="title" id="CD006281-sec-0003">Search methods</h3> <p>We searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, and ISI Web of Science conference proceedings in October 2018. We also searched two trials registries to identify unpublished trials (October 2018). </p> </section> <section id="CD006281-sec-0004"> <h3 class="title" id="CD006281-sec-0004">Selection criteria</h3> <p>We sought all randomised controlled trials (RCTs) or quasi‐RCTs that examined the efficacy of drug treatment for SMA type I. Included participants had to fulfil clinical criteria and have a genetically confirmed deletion or mutation of the <i>SMN1</i> gene (5q11.2‐13.2). </p> <p>The primary outcome measure was age at death or full‐time ventilation. Secondary outcome measures were acquisition of motor milestones, i.e. head control, rolling, sitting or standing, motor milestone response on disability scores within one year after the onset of treatment, and adverse events and serious adverse events attributable to treatment during the trial period. </p> <p>Treatment strategies involving <i>SMN1</i> gene replacement with viral vectors are out of the scope of this review. </p> </section> <section id="CD006281-sec-0005"> <h3 class="title" id="CD006281-sec-0005">Data collection and analysis</h3> <p>We followed standard Cochrane methodology.</p> </section> <section id="CD006281-sec-0006"> <h3 class="title" id="CD006281-sec-0006">Main results</h3> <p>We identified two RCTs: one trial of intrathecal nusinersen in comparison to a sham (control) procedure in 121 randomised infants with SMA type I, which was newly included at this update, and one small trial comparing riluzole treatment to placebo in 10 children with SMA type I. </p> <p>The RCT of intrathecally‐injected nusinersen was stopped early for efficacy (based on a predefined Hammersmith Infant Neurological Examination‐Section 2 (HINE‐2) response). At the interim analyses after 183 days of treatment, 41% (21/51) of nusinersen‐treated infants showed a predefined improvement on HINE‐2, compared to 0% (0/27) of participants in the control group. This trial was largely at low risk of bias. </p> <p>Final analyses (ranging from 6 months to 13 months of treatment), showed that fewer participants died or required full‐time ventilation (defined as more than 16 hours daily for 21 days or more) in the nusinersen‐treated group than the control group (hazard ratio (HR) 0.53, 95% confidence interval (CI) 0.32 to 0.89; N = 121; a 47% lower risk; moderate‐certainty evidence). A proportion of infants in the nusinersen group and none of 37 infants in the control group achieved motor milestones: 37/73 nusinersen‐treated infants (51%) achieved a motor milestone response on HINE‐2 (risk ratio (RR) 38.51, 95% CI 2.43 to 610.14; N = 110; moderate‐certainty evidence); 16/73 achieved head control (RR 16.95, 95% CI 1.04 to 274.84; moderate‐certainty evidence); 6/73 achieved independent sitting (RR 6.68, 95% CI 0.39 to 115.38; moderate‐certainty evidence); 7/73 achieved rolling over (RR 7.70, 95% CI 0.45 to 131.29); and 1/73 achieved standing (RR 1.54, 95% CI 0.06 to 36.92; moderate‐certainty evidence). Seventy‐one per cent of nusinersen‐treated infants versus 3% of infants in the control group were responders on the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) measure of motor disability (RR 26.36, 95% CI 3.79 to 183.18; N = 110; moderate‐certainty evidence). </p> <p>Adverse events and serious adverse events occurred in the majority of infants but were no more frequent in the nusinersen‐treated group than the control group (RR 0.99, 95% CI 0.92 to 1.05 and RR 0.70, 95% CI 0.55 to 0.89, respectively; N = 121; moderate‐certainty evidence). </p> <p>In the riluzole trial, three of seven children treated with riluzole were still alive at the ages of 30, 48, and 64 months, whereas all three children in the placebo group died. None of the children in the riluzole or placebo group developed the ability to sit, which was the only milestone reported. There were no adverse effects. The certainty of the evidence for all measured outcomes from this study was very low, because the study was too small to detect or rule out an effect, and had serious limitations, including baseline differences. This trial was stopped prematurely because the pharmaceutical company withdrew funding. </p> <p>Various trials and studies investigating treatment strategies other than nusinersen, such as <i>SMN2</i> augmentation by small molecules, are ongoing. </p> </section> <section id="CD006281-sec-0007"> <h3 class="title" id="CD006281-sec-0007">Authors' conclusions</h3> <p>Based on the very limited evidence currently available regarding drug treatments for SMA type 1, intrathecal nusinersen probably prolongs ventilation‐free and overall survival in infants with SMA type I. It is also probable that a greater proportion of infants treated with nusinersen than with a sham procedure achieve motor milestones and can be classed as responders to treatment on clinical assessments (HINE‐2 and CHOP INTEND). The proportion of children experiencing adverse events and serious adverse events on nusinersen is no higher with nusinersen treatment than with a sham procedure, based on evidence of moderate certainty. It is uncertain whether riluzole has any effect in patients with SMA type I, based on the limited available evidence. Future trials could provide more high‐certainty, longer‐term evidence to confirm this result, or focus on comparing new treatments to nusinersen or evaluate them as an add‐on therapy to nusinersen. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006281-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006281-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006281-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006281-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD006281-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006281-abs-0007">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006281-abs-0004" lang="en"> <h3>Drug treatment for spinal muscular atrophy type I</h3> <p><b>What is the aim of this review?</b> </p> <p>The aim of this Cochrane Review was to look at the effects of drug treatments on spinal muscular atrophy (SMA) type I, in terms of age at death or full‐time ventilation and the ability to reach motor milestones, e.g. rolling, sitting or standing, within one year after beginning treatment, and any adverse events. </p> <p><b>Key messages</b> </p> <p>Nusinersen probably increases ventilation‐free and overall survival in children with SMA type I. Nusinersen may improve the proportion of infants achieving motor milestones. Adverse events and serious adverse events are probably not more common with nusinersen injection than with a sham procedure. </p> <p>It is uncertain whether riluzole has any effect in SMA type I, based on the limited available evidence. </p> <p><b>What was studied in the review?</b> </p> <p>SMA is a disorder with onset in childhood and adolescence and leads to increasing muscle weakness. SMA type I, also known as Werdnig‐Hoffman disease, is the most severe form of SMA and begins before the age of six months. Untreated children with SMA type I will never be able to sit without support and in general die or develop respiratory insufficiency and need non‐invasive ventilation before they reach the age of two years. </p> <p>At the time of the previous versions of the review there was no known treatment to slow down or cure SMA type I. We updated the review to include emerging evidence. </p> <p>Cochrane review authors collected relevant studies and found two trials. Both studies were funded by pharmaceutical companies. One trial, in 121 infants with SMA type I, studied nusinersen, which is an antisense oligonucleotide drug, given by injection into the spinal canal. The researchers compared the effects of nusinersen with a sham procedure in the control group. This trial stopped early because results showed that nusinersen improved the proportion of infants achieving motor milestones. The other trial compared riluzole to placebo and involved 10 infants with SMA type I. This trial was stopped prematurely because the pharmaceutical company withdrew funding. </p> <p><b>What are the main results of the review</b> </p> <p>Results were not all reported at the same follow‐up point, as the trial was stopped before some participants completed the planned follow‐up. Nusinersen probably reduced the risk of death or progression to full‐time ventilation (assisted breathing) by 47% compared to the control group. The evidence is also moderately certain that the percentage of children with a response on objective clinical assessments of motor function was higher in the nusinersen‐treated group than the sham procedure group (51% versus 0% on the Hammersmith Infant Neurological Examination‐Section 2 (HINE‐2) and 71% versus 3% on the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)). Infants treated with nusinersen are probably also more likely to reach developmental milestones: 16 of the 73 treated infants achieved head control, six achieved independent sitting, seven achieved the ability to roll over, and one achieved the ability to stand; none of the 37 infants in the control group achieved any of these milestones. </p> <p>There was probably little difference between the nusinersen‐treated and control group in the number of infants with adverse events; the majority experienced adverse events. Serious adverse events were probably no more common with nusinersen than with the sham procedure. </p> <p>One study compared riluzole treatment to placebo (an identical, but inactive treatment) in 10 children with SMA type I. The certainty of the evidence was very low, mainly because the study was too small to detect or rule out an effect. In this trial, all three children in the placebo group and four of the seven children in the riluzole group died within 12 months of the study. Three of the seven children treated with riluzole were still alive at the ages of 30, 48, and 64 months. None of the children in the riluzole or placebo group developed the ability to sit. The evidence can neither confirm nor rule out an effect of riluzole in children with SMA type I because of its small size and severe limitations. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>We searched for studies that had been published up to October 2018.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006281-sec-0104" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006281-sec-0104"></div> <h3 class="title" id="CD006281-sec-0105">Implications for practice</h3> <section id="CD006281-sec-0105"> <p>Evidence of moderate certainty shows that the antisense oligonucleotide therapy, nusinersen, shows efficacy in patients with spinal muscular atrophy (SMA) type I by prolonging survival and improving motor function. Moderate‐certainty evidence also indicates that a greater proportion of infants treated with nusinersen than with a sham procedure achieve motor milestones and may be classed as responders to treatment on clinical assessments (Hammersmith Infant Neurological Examination‐Section 2 (HINE‐2) and Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)). The evidence is also of moderate certainty that the proportion of children with adverse events and serious adverse events on intrathecal nusinersen is no higher with nusinersen than with a sham procedure. </p> <p>There is no evidence for or against the use of riluzole, the only other drug studied in a randomised trial, as the certainty of evidence is too low for conclusions to be drawn. </p> <p>Other trials are ongoing or awaiting results.</p> </section> <h3 class="title" id="CD006281-sec-0106">Implications for research</h3> <section id="CD006281-sec-0106"> <p>Since antisense oligonucleotide therapy with nusinersen has been found to be an efficacious drug therapy for SMA type I in a clinical trial, future trials should preferably compare new treatments to nusinersen or be evaluated as an add‐on therapy to nusinersen. </p> <p>Most trials investigating new therapies are focused on the early phases of the disease, since motor improvement or lack of decline is the simplest way to establish drug efficacy. However, therapies should also be sought to prevent disease progression, conserve motor function, and improve quality of life for those who have a longer disease duration. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006281-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006281-sec-0022"></div> <div class="table" id="CD006281-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intrathecal injected nusinersen compared to sham procedure for infants with SMA and 2 SMN2 copies</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Intrathecal injected nusinersen compared to sham procedure for infants with SMA and 2 <i>SMN2</i> copies</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infants with SMA and 2 <i>SMN2</i> copies<br/> <b>Setting:</b> in‐hospital treatment for outpatient clinic<br/> <b>Intervention:</b> intrathecal injected nusinersen<br/> <b>Comparison:</b> sham procedure </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with sham procedure</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with intrathecal injected nusinersen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Time from birth until death or full‐time ventilation</b><sup>a</sup><br/> Follow‐up: range 6 months to 13 months<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.53</b><br/> (0.32 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>121<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>This represents a 47% lower risk of death or full‐time ventilation with nusinersen than with the sham procedure </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 100</b><br/> (31 to 64) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acquisition of head control</b> within one year after the onset of treatment<br/> Follow‐up: range 6 months to 13 months<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 of 37 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 of 73 participants in the nusinersen‐treated group achieved head control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 16.95</b> (1.04 to 274.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquisition of the ability to sit</b> within one year after the onset of treatment<br/> Follow‐up: range 6 months to 13 months<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 of 37 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 of 73 participants in the nusinersen‐treated group achieved the ability to sit independently</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 6.68</b> </p> <p>(0.39 to 115.38)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquisition of the ability to stand</b> within one year after the onset of treatment<br/> Follow‐up: range 6 months to 13 months<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 of 37 participants in the sham procedure group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 of 73 participants in the nusinersen‐treated group achieved the ability to stand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.54</b> </p> <p>(0.06 to 36.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in motor disability score</b> ‐ response on HINE‐2 within one year after the onset of treatment<sup>e</sup><br/> Follow‐up: range 6 months to 13 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 of 37 participants in the sham procedure group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 of 73 participants in the nusinersen‐treated group showed a motor milestone response on the HINE‐2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 38.51</b> (2.43 to 610.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events attributable to treatment</b> </p> <p>Measured as adverse events (all)<br/> Follow‐up: range 6 months to 13 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.99</b> </p> <p>(0.92 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>121<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Including bleeding risk from thrombocytopenia, renal toxicity, hyponatraemia, reduced growth, rash and possible (cerebral) vasculitis, hepatotoxicity, QTc interval prolongation on electrocardiogram, aspiration, infections, gastrointestinal problems </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>976 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>966 per 1000</b> </p> <p>(898 to 1000)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Severe adverse events attributable to treatment</b> </p> <p>Measured as severe adverse events (all)<br/> Follow‐up: range 6 months to 13 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.70</b> </p> <p>(0.55 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>121<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Including respiratory problems, cardiorespiratory arrest, death, brain injury, hypoxic ischaemic encephalopathy </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>805 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>563 per 1000</b> </p> <p>(443 to 716)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CHOP INTEND</b> : Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders; <b>HINE‐2</b> : Hammersmith Infant Neurological Examination‐Section 2; <b>CI</b> : confidence interval; <b>HR</b> : hazard ratio; <b>RCT</b> : randomised controlled trial; <b>RR</b> : risk ratio; <b>SMA</b>: spinal muscular atrophy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Defined as a requirement for 16 hours of ventilation per day regardless of whether via tracheostomy, tube or mask.<br/> <sup>b</sup>We downgraded the certainty of the evidence once for risk of bias and imprecision (not sufficient to downgrade once for each). A slight baseline imbalance meant that children in the nusinersen‐treated group had an earlier onset and were more severely affected by respiratory and bulbar problems. This baseline imbalance in factors related to respiratory decline would tend to favour the control intervention for this outcome. Although the effect of nusinersen is large, there is some degree of uncertainty in the effect estimate arising from imprecision in a single study of this size.<br/> <sup>c</sup>Based on the final analysis. An interim analysis of motor milestones (HINE‐2) was performed on all participants who had a day 183 visit. The study was then stopped for significant benefit from nusinersen. Final analysis was performed on data including participants fulfilling at least six months of trial enrolment.<br/> <sup>d</sup>We downgraded the certainty of the evidence once for risk of bias and imprecision (not sufficient to downgrade once for each). There was slight baseline imbalance and there is some degree of uncertainty in the effect estimate arising from imprecision in a single study of this size. We did not downgrade the motor milestone outcome results further for imprecision, in spite of wide CI. The absence of events in the control group is consistent with the natural history of SMA type 1 and a response represents a large treatment effect.<br/> <sup>e</sup>Response was defined according to scores on the HINE‐2, which assesses the development of motor function through the achievement of motor milestones; in this trial, the scores accounted for 7 of the 8 motor milestone categories, excluding voluntary grasp. Infants were considered to have a motor milestone response if they met the following two criteria: improvement in at least one category (i.e. an increase in the score for head control, rolling, sitting, crawling, standing, or walking of ≥ 1 point, an increase in the score for kicking of ≥ 2 points, or achievement of the maximal score for kicking) and more categories with improvement than categories with worsening (i.e. a decrease was defined as ≥ 1 point decrease in the score for head control, rolling, sitting, crawling, standing, or walking and a decrease in the score for kicking was defined as a decrease of ≥ 2 points).<br/> <sup>f</sup>We downgraded one level for imprecision because the small sample size and shortened study duration mean that the study is unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006281-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Riluzole compared to placebo for children with SMA type I</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Riluzole compared to placebo for children with SMA type I</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with SMA type I<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> riluzole<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Impact</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>Commments</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time from birth until death or full‐time ventilation</b><br/> Follow‐up: range 1 month to 64 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In the 3 children in the placebo group, the median age at death was 8 months (range 6 to 13 months). 4/7 children treated with riluzole died during the trial, at a median age of 17 months (range 5 to 25 months); the remaining 3 children treated with riluzole were still alive at 30, 48 and 64 months. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acquisition of head control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquisition of the ability to sit</b> <br/> Follow‐up: range 1 month to 64 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>None of the children in the riluzole or the placebo group acquired the ability to sit (follow‐up was extended up to 30 to 64 months in the children treated with riluzole). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquisition of the ability to stand</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in motor disability score</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events attributable to treatment</b><br/> Follow‐up: range 1 month to 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No adverse events occurred in children treated with placebo or riluzole.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe adverse events attributable to treatment</b><br/> Follow‐up: range 1 months to 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No adverse events occurred in children treated with placebo or riluzole.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>RCT</b> : randomised controlled trial; <b>SMA</b>: spinal muscular atrophy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the certainty of the evidence three levels: twice for serious imprecision, because of the small cohort, and once for risk of bias as there were baseline differences between treatment and control groups. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006281-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006281-sec-0023"></div> <section id="CD006281-sec-0024"> <h3 class="title" id="CD006281-sec-0024">Description of the condition</h3> <p>Spinal muscular atrophy (SMA) is a genetic anterior horn cell disorder with onset ranging from infancy to adolescence and even adulthood. It is caused by the homozygous deletion or heterozygous deletion in combination with a point mutation in the second allele of the survival motor neurone 1 (<i>SMN1</i>) gene that has been mapped to chromosome 5q11.2‐13.3 (<a href="./references#CD006281-bbs2-0050" title="BrzustowiczLM , LehnerT , CastillaLH , PenchaszadehGK , WilhelmsenKC , DanielsR , et al. Genetic mapping of chronic childhood‐onset spinal muscular atrophy to chromosome 5q11.2‐13.3. Nature1990;344(6266):540‐1. ">Brzustowicz 1990</a>; <a href="./references#CD006281-bbs2-0078" title="GilliamTC , BrzustowiczLM , CastillaLH , LehnerT , PenchaszadehGK , DanielsRJ , et al. Genetic homogeneity between acute and chronic forms of spinal muscular atrophy. Nature1990;345(6278):823‐5. ">Gilliam 1990</a>; <a href="./references#CD006281-bbs2-0112" title="LefebvreS , BurglenL , ReboulletS , ClermontO , BurletP , ViolletL , et al. Identification and characterization of a spinal muscular atrophy‐determining gene. Cell1995;80(1):155‐65. ">Lefebvre 1995</a>; <a href="./references#CD006281-bbs2-0128" title="MelkiJ , AbdelhakS , ShethP , BachelotMF , BurletP , MarcadetA , et al. Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q. Nature1990;344(6268):767‐8. ">Melki 1990a</a>; <a href="./references#CD006281-bbs2-0129" title="MelkiJ , ShethP , AbdelhakS , BurletP , BachelotMF , LathropMG , et al. Mapping of acute (type I) spinal muscular atrophy to chromosome 5q12‐q14. The French Spinal Muscular Atrophy Investigators. Lancet1990;336(8710):271‐3. ">Melki 1990b</a>). SMA has an annual incidence of 1 in 6000 to 12,000 (<a href="./references#CD006281-bbs2-0033" title="ArkbladE , TuliniusM , KroksmarkAK , HenricssonM , DarinN . A population‐based study of genotypic and phenotypic variability in children with spinal muscular atrophy. Acta Paediatrica2009;98(5):865‐72. ">Arkblad 2009</a>; <a href="./references#CD006281-bbs2-0058" title="CobbenJM , deVisserM , SchefferH . From gene to disease; 'survival' motor neuron protein and hereditary proximal spinal muscle atrophy. Nederlands Tijdschrift voor Geneeskunde2001;145(52):2525‐7. ">Cobben 2001</a>; <a href="./references#CD006281-bbs2-0143" title="NicoleS , DiazCC , FrugierT , MelkiJ . Spinal muscular atrophy: recent advances and future prospects. Muscle &amp; Nerve2002;26(1):4‐13. ">Nicole 2002</a>). It is clinically characterised by muscle weakness, proximal more than distal and in the legs more than the arms, that progresses over time (<a href="./references#CD006281-bbs2-0100" title="IannacconeST , BurghesAH . Spinal muscular atrophies. In: RahmanPourmand , YadollahHarati editor(s). Neuromuscular Disorders. Philadelphia: Lippincott Williams and Wilkins, 2001:83‐98. ">Iannaccone 2001</a>; <a href="./references#CD006281-bbs2-0181" title="TalbotK . Spinal muscular atrophy. Journal of Inherited Metabolic Diseases1999;22(4):545‐54. ">Talbot 1999</a>). There are indications that other structures than anterior horn cells, including the neuromuscular junction and muscle may also be sensitive to the deficiency of SMN protein due to the homozygous deletion of the <i>SMN1</i> gene (<a href="./references#CD006281-bbs2-0047" title="BraunS , CroizatB , LagrangeMC , WarterJM , PoindronP . Constitutive muscular abnormalities in culture in spinal muscular atrophy. Lancet1995;345(8951):694‐5. [PUBMED: 7741893] ">Braun 1995</a>; <a href="./references#CD006281-bbs2-0056" title="Cifuentes‐DiazC , FrugierT , MelkiJ . Spinal muscular atrophy. Seminars in Pediatric Neurology2002;9(2):145‐50. [PUBMED: 12138998] ">Cifuentes‐Diaz 2002</a>; <a href="./references#CD006281-bbs2-0105" title="KariyaS , ParkGH , Maeno‐HikichiY , LeykekhmanO , LutzC , ArkovitzMS , et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Human Molecular Genetics2008;17(16):2552‐69. [PUBMED: 18492800] ">Kariya 2008</a>; <a href="./references#CD006281-bbs2-0140" title="MurrayLM , ComleyLH , ThomsonD , ParkinsonN , TalbotK , GillingwaterTH . Selective vulnerability of motor neurons and dissociation of pre‐ and post‐synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Human Molecular Genetics2008;17(7):949‐62. [PUBMED: 18065780] ">Murray 2008</a>). </p> <p>Weakness shows a particular pattern, with the best known example, axial and proximal weakness with weakened intercostal muscles and sparing of the diaphragm (<a href="./references#CD006281-bbs2-0110" title="KroksmarkAK , BeckungE , TuliniusM . Muscle strength and motor function in children and adolescents with spinal muscular atrophy II and III. European Journal of Paediatric Neurology2001;5(5):191‐8. ">Kroksmark 2001</a>; <a href="./references#CD006281-bbs2-0182" title="ThomasNH , DubowitzV . The natural history of type I (severe) spinal muscular atrophy. Neuromuscular Disorders1994;4(5‐6):497‐502. ">Thomas 1994</a>). Survival depends primarily on respiratory function (<a href="./references#CD006281-bbs2-0066" title="DubowitzV . Chaos in the classification of SMA: a possible resolution. Neuromuscular Disorders1995;5(1):3‐5. ">Dubowitz 1995</a>; <a href="./references#CD006281-bbs2-0164" title="RussmanBS , IannaconeST , BuncherCR , SamahaFJ , WhiteM , PerkinsB , et al. Spinal muscular atrophy: new thoughts on the pathogenesis and classification schema. Journal of Child Neurology1992;7(4):347‐53. ">Russman 1992</a>; <a href="./references#CD006281-bbs2-0181" title="TalbotK . Spinal muscular atrophy. Journal of Inherited Metabolic Diseases1999;22(4):545‐54. ">Talbot 1999</a>). Although the face is often spared, tongue fasciculations and facial weakness are not unusual findings (<a href="./references#CD006281-bbs2-0098" title="IannacconeST , BrowneRH , SamahaFJ , BuncherCR . Prospective study of spinal muscular atrophy before age 6 years. DCN/SMA Group. Pediatric Neurology1993;9(3):187‐93. ">Iannaccone 1993</a>). The cognitive function of SMA patients is normal and in infantile cases there is often a striking discrepancy between alertness and the ability to move (<a href="./references#CD006281-bbs2-0099" title="IannacconeST . Spinal muscular atrophy. Seminars in Neurology1998;18(1):19‐26. ">Iannaccone 1998</a>; <a href="./references#CD006281-bbs2-0182" title="ThomasNH , DubowitzV . The natural history of type I (severe) spinal muscular atrophy. Neuromuscular Disorders1994;4(5‐6):497‐502. ">Thomas 1994</a>). </p> <p>Classification of SMA according to the International SMA Collaboration distinguishes five SMA types (0 to IV) and is based on age of onset and maximal acquired motor function (<a href="./references#CD006281-bbs2-0071" title="FinkelR , BertiniE , MuntoniF , MercuriE , ENMC SMA Workshop Study Group. 209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7‐9 November 2014, Heemskerk, The Netherlands. Neuromuscular Disorders2015;25(7):593‐602. ">Finkel 2015</a>; <a href="./references#CD006281-bbs2-0131" title="MercuriE , BertiniE , IannacconeST . Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurology2012;11(5):443‐52. ">Mercuri 2012</a>; <a href="./references#CD006281-bbs2-0139" title="MunsatTL , DaviesKE . International SMA consortium meeting (26‐28 June 1992, Bonn, Germany). Neuromuscular Disorders1992;2(5‐6):423‐8. ">Munsat 1992</a>). SMA type 0, and IV represent the two ends of the spectrum of SMA, which are out of the scope of this review. SMA types II and III are the topic of a separate Cochrane Review (<a href="./references#CD006281-bbs2-0192" title="WadmanRI , van derPolWL , BosboomWMJ , van denBergLH , IannacconeST , VranckenAFJE . Drug treatment for spinal muscular atrophy types II and III. Cochrane Database of Systematic Reviews (in press). [DOI: 10.1002/14651858.CD006282.pub5] ">Wadman 2018</a>). </p> <p>SMA type I is the most common form and is also known as Werdnig‐Hoffmann disease, acute SMA, and infantile‐onset SMA. The age of onset is before six months and it is further characterised by severe progressive muscle weakness and hypotonia (<a href="./references#CD006281-bbs2-0099" title="IannacconeST . Spinal muscular atrophy. Seminars in Neurology1998;18(1):19‐26. ">Iannaccone 1998</a>). Children with SMA type I will never be able to sit without support, and respiratory insufficiency usually occurs before the age of two years (<a href="./references#CD006281-bbs2-0059" title="CobbenJM , LemminkHH , SnoeckI , BarthPA , van derLeeJH , deVisserM . Survival in SMA type I: a prospective analysis of 34 consecutive cases. Neuromuscular Disorders2008;18(7):541‐4. ">Cobben 2008</a>; <a href="./references#CD006281-bbs2-0070" title="FinkelRS , McDermottMP , KaufmannP , DarrasBT , ChungWK , SprouleDM , et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology2014;83(9):810‐7. ">Finkel 2014</a>; <a href="./references#CD006281-bbs2-0098" title="IannacconeST , BrowneRH , SamahaFJ , BuncherCR . Prospective study of spinal muscular atrophy before age 6 years. DCN/SMA Group. Pediatric Neurology1993;9(3):187‐93. ">Iannaccone 1993</a>; <a href="./references#CD006281-bbs2-0148" title="OskouiM , LevyG , GarlandCJ , GrayJM , O'HagenJ , DeVivoDC , et al. The changing natural history of spinal muscular atrophy type I. Neurology2007;69:1931‐6. ">Oskoui 2007</a>; <a href="./references#CD006281-bbs2-0151" title="ParkerGC , LiX , AnguelovRA , TothG , CristescuA , AcsadiG . Survival motor neuron protein regulates apoptosis in an in vitro model of spinal muscular atrophy. Neurotoxicity Research2008;13(1):39‐48. ">Parker 2008</a>; <a href="./references#CD006281-bbs2-0182" title="ThomasNH , DubowitzV . The natural history of type I (severe) spinal muscular atrophy. Neuromuscular Disorders1994;4(5‐6):497‐502. ">Thomas 1994</a>). It is one of the most important causes of death due to a genetic disease in childhood (<a href="./references#CD006281-bbs2-0143" title="NicoleS , DiazCC , FrugierT , MelkiJ . Spinal muscular atrophy: recent advances and future prospects. Muscle &amp; Nerve2002;26(1):4‐13. ">Nicole 2002</a>). </p> <p>The SMN region contains two <i>SMN</i> genes, the telomeric <i>SMN</i> gene (<i>SMN1</i> or <i>SMNt</i> ) and the centromeric <i>SMN</i> gene (<i>SMN2</i> or <i>SMNc</i>) (<a href="./references#CD006281-bbs2-0099" title="IannacconeST . Spinal muscular atrophy. Seminars in Neurology1998;18(1):19‐26. ">Iannaccone 1998</a>; <a href="./references#CD006281-bbs2-0143" title="NicoleS , DiazCC , FrugierT , MelkiJ . Spinal muscular atrophy: recent advances and future prospects. Muscle &amp; Nerve2002;26(1):4‐13. ">Nicole 2002</a>). The <i>SMN1</i> and <i>SMN2</i> gene are almost identical, but a crucial C to T nucleotide difference in exon 7 results in its exclusion from most SMN2 mRNA copies (<a href="./references#CD006281-bbs2-0112" title="LefebvreS , BurglenL , ReboulletS , ClermontO , BurletP , ViolletL , et al. Identification and characterization of a spinal muscular atrophy‐determining gene. Cell1995;80(1):155‐65. ">Lefebvre 1995</a>; <a href="./references#CD006281-bbs2-0119" title="LorsonCL , HahnenE , AndrophyEJ , WirthB . A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proceedings of the National Academy of Sciences of the United States of America1999;96:6307‐11. ">Lorson 1999</a>). Consequently, there is no transcription of stable SMN protein from the <i>SMN1</i> gene and the <i>SMN2</i> gene is not able to produce enough stable SMN protein (<a href="./references#CD006281-bbs2-0057" title="CobbenJM , van derSteege , GrootscholtenP , deVisserM , SchefferH , BuysCH . Deletions of the survival motor neuron gene in unaffected siblings of patients with spinal muscular atrophy. American Journal of Human Genetics1995;57(4):805‐8. ">Cobben 1995</a>; <a href="./references#CD006281-bbs2-0112" title="LefebvreS , BurglenL , ReboulletS , ClermontO , BurletP , ViolletL , et al. Identification and characterization of a spinal muscular atrophy‐determining gene. Cell1995;80(1):155‐65. ">Lefebvre 1995</a>; <a href="./references#CD006281-bbs2-0143" title="NicoleS , DiazCC , FrugierT , MelkiJ . Spinal muscular atrophy: recent advances and future prospects. Muscle &amp; Nerve2002;26(1):4‐13. ">Nicole 2002</a>). The clinical severity of the disease is related to the number of copies of the <i>SMN2</i> gene (<a href="./references#CD006281-bbs2-0069" title="FeldkotterM , SchwarzerV , WirthR , WienkerTF , WirthB . Quantitative analyses of SMN1 and SMN2 based on real‐time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. American Journal of Human Genetics2002;70(2):358‐68. ">Feldkotter 2002</a>; <a href="./references#CD006281-bbs2-0088" title="HaradaY , SutomoR , SadewaAH , AkutsuT , TakeshimaY , WadaH , et al. Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity. Journal of Neurology2002;249(9):1211‐9. ">Harada 2002</a>; <a href="./references#CD006281-bbs2-0154" title="PiepersS , van denBergLH , BrugmanF , SchefferH , Ruiterkamp‐VersteegM , vanEngelenBG , et al. A natural history study of late onset spinal muscular atrophy types 3b and 4. Journal of Neurology2008;255(9):1400‐4. [DOI: 10.1007/s00415‐008‐0929‐0] ">Piepers 2008</a>; <a href="./references#CD006281-bbs2-0179" title="SwobodaKJ , PriorTW , ScottCB , McNaughtTP , WrideMC , ReynaSP , et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Annals of Neurology2005;57(5):704‐12. ">Swoboda 2005</a>; <a href="./references#CD006281-bbs2-0191" title="WadmanRI , StamM , GijzenM , LemminkHH , SnoeckIN , WijngaardeCA , et al. Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0‐4. Journal of Neurology, Neurosurgery and Psychiatry2017;88(4):365‐7. ">Wadman 2017a</a>). </p> <p>The cellular functions of the SMN protein are multiple, but its vital role in motor neurons is not known (<a href="./references#CD006281-bbs2-0178" title="SumnerCJ . Molecular mechanisms of spinal muscular atrophy. Journal of Child Neurology2007;22(8):979‐89. ">Sumner 2007</a>). SMN protein is important for ribonucleoprotein (RNP) assembly (<a href="./references#CD006281-bbs2-0051" title="BurghesAH , BeattieCE . Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?. Nature Reviews Neuroscience2009;10(8):597‐609. ">Burghes 2009</a>; <a href="./references#CD006281-bbs2-0077" title="GendronNH , MacKenzieAE . Spinal muscular atrophy: molecular pathophysiology. Current Opinion in Neurology1999;12(2):137‐42. ">Gendron 1999</a>; <a href="./references#CD006281-bbs2-0102" title="JablonkaS , RossollW , SchrankB , SendtnerM . The role of SMN in spinal muscular atrophy. Journal of Neurology2000;247(Suppl 1):I37‐42. ">Jablonka 2000</a>; <a href="./references#CD006281-bbs2-0113" title="LefebvreS , BurglenL , FrezalJ , MunnichA , MelkiJ . The role of the SMN gene in proximal spinal muscular atrophy. Human Molecular Genetics1998;7(10):1531‐6. ">Lefebvre 1998</a>; <a href="./references#CD006281-bbs2-0153" title="PellizzoniL , KataokaN , CharrouxB , DreyfussG . A novel function for SMN, the spinal muscular atrophy disease gene product, in pre‐mRNA splicing. Cell1998;95(5):615‐24. ">Pellizzoni 1998</a>), motor axon outgrowth and axonal transport (<a href="./references#CD006281-bbs2-0126" title="McWhorterML , MonaniUR , BurghesAH , BeattieCE . Knockdown of the survival motor neuron (smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. The Journal of Cell Biology2003;162(5):919‐31. ">McWhorter 2003</a>; <a href="./references#CD006281-bbs2-0163" title="RossollW , JablonkaS , AndreassiC , KröningAK , KarleK , MonaniUR , et al. Smn, the spinal muscular atrophy‐determining gene product, modulates axon growth and localization of beta‐actin mRNA in growth cones of motoneurons. Journal of Cell Biology2003;163(4):801‐12. ">Rossoll 2003</a>), protection against superoxide dismutase 1 (SOD1) toxicity (<a href="./references#CD006281-bbs2-0207" title="ZouT , IlangovanR , YuF , XuZ , ZhouJ . SMN protects cells against mutant SOD1 toxicity by increasing chaperone activity. Biochemical and Biophysical Research Communication2007;364(4):850‐5. ">Zou 2007</a>), endocytosis (<a href="./references#CD006281-bbs2-0094" title="HosseinibarkooieS , PetersM , Torres‐BenitoL , RastetterRH , HupperichK , HoffmannA , et al. The power of human protective modifiers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype. American Journal of Human Genetics2016;99(3):647‐65. ">Hosseinibarkooie 2016</a>; <a href="./references#CD006281-bbs2-0161" title="RiesslandM , KaczmarekA , SchneiderS , SwobodaKJ , LöhrH , BradlerC , et al. Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis. American Journal of Human Genetics2017;100(2):297‐315. ">Riessland 2017</a>), and ubiquitination homeostasis (<a href="./references#CD006281-bbs2-0196" title="WishartTM , MutsaersCA , RiesslandM , ReimerMM , HunterG , HannamML , et al. Dysregulation of ubiquitin homeostasis and β‐catenin signaling promote spinal muscular atrophy. Journal of Clinical Investigation2014;124(4):1821‐34. ">Wishart 2014</a>). </p> </section> <section id="CD006281-sec-0025"> <h3 class="title" id="CD006281-sec-0025">Description of the intervention</h3> <p>Drug treatment for SMA type I is urgently needed. Management of SMA consists of preventing or treating the complications (<a href="./references#CD006281-bbs2-0072" title="FinkelRS , MercuriE , MeyerOH , SimondsAK , SchrothMK , GrahamRJ , et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromusculular Disordorders2018;28(3):197‐207. ">Finkel 2018</a>; <a href="./references#CD006281-bbs2-0099" title="IannacconeST . Spinal muscular atrophy. Seminars in Neurology1998;18(1):19‐26. ">Iannaccone 1998</a>; <a href="./references#CD006281-bbs2-0132" title="MercuriE , FinkelRS , MuntoniF , WirthB , MontesJ , MainM , et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscular Disorders2018;28(2):103‐15. ">Mercuri 2018</a>; <a href="./references#CD006281-bbs2-0193" title="WangCH , FinkelRS , BertiniES , SchrothM , SimondsA , WongB , et al. Consensus statement for standard of care in spinal muscular atrophy. Journal of Child Neurology2007;22(8):1027‐49. ">Wang 2007</a>). Administration of agents capable of increasing the expression of SMN protein levels may improve the outcome in SMA (<a href="./references#CD006281-bbs2-0069" title="FeldkotterM , SchwarzerV , WirthR , WienkerTF , WirthB . Quantitative analyses of SMN1 and SMN2 based on real‐time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. American Journal of Human Genetics2002;70(2):358‐68. ">Feldkotter 2002</a>; <a href="./references#CD006281-bbs2-0076" title="GavrilinaTO , McGovernVL , WorkmanE , CrawfordTO , GogliottiRG , DiDonatoCJ , et al. Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle‐specific SMN expression has no phenotypic effect. Human Molecular Genetics2008;17(8):1063‐75. ">Gavrilina 2008</a>; <a href="./references#CD006281-bbs2-0119" title="LorsonCL , HahnenE , AndrophyEJ , WirthB . A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proceedings of the National Academy of Sciences of the United States of America1999;96:6307‐11. ">Lorson 1999</a>). Transcriptional <i>SMN2</i> activation, facilitation or correction of <i>SMN2</i> splicing, translational activation, and stabilisation of the full‐length SMN protein are possible therapeutic strategies for SMA. Other strategies are improvement of motor neuron viability by neuroprotective or neurotrophic agents (<a href="./references#CD006281-bbs2-0122" title="LunnMR , WangCH . Spinal muscular atrophy. Lancet2008;371(9630):2120‐33. ">Lunn 2008</a>; <a href="./references#CD006281-bbs2-0183" title="ThurmondJ , ButchbachME , PalomoM , PeaseB , RaoM , BedellL , et al. Synthesis and biological evaluation of novel 2,4‐diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. Journal of Medicinal Chemistry2008;51(3):449‐69. ">Thurmond 2008</a>; <a href="./references#CD006281-bbs2-0195" title="WirthB , BrichtaL , HahnenE . Spinal muscular atrophy: from gene to therapy. Seminars in Pediatric Neurology2006;13(2):121‐31. ">Wirth 2006</a>). Recently, trials with splice site modulators (<a href="./references#CD006281-bbs2-0023" title="NCT02462759 . A study to assess the safety and tolerability of ISIS 396443 (ISIS SMNRx) in participants with spinal muscular atrophy (SMA). (EMBRACE) [A phase 2, randomized, double‐blind, sham‐procedure controlled study to assess the safety and tolerability and explore the efficacy of ISIS 396443 (BIIB058) administered intrathecally in subjects with spinal muscular atrophy who are not eligible to participate in the clinical studies ISIS 396443‐CS3B or ISIS 396443‐CS4]. clinicaltrials.gov/show/NCT02462759 (first received 14 May 2015). [CTG: NCT02462759; EudraCT : EUCTR2014‐003657‐33‐DE; 232SM202] ">EMBRACE 2015</a>; <a href="./references#CD006281-bbs2-0007" title="FinkelR , ChiribogaC , VajsarJ , DayJ , MontesJ , DeVivoD , et al. Interim results of a phase 2 clinical study of nusinersen (ISIS‐SMNRx) in patients with infantile‐onset spinal muscular atrophy. Annals of Neurology2016;80(Suppl 20):S371‐2. FinkelRS , ChiribogaCA , VajsarJ , DayJW , MontesJ , DeVivoDC , et al. Treatment of infantile‐onset spinal muscular atrophy with nusinersen: a phase 2, open‐label, dose‐escalation study. Lancet2016;388(10063):3017‐26. NCT01839656 . A study to assess the safety and pharmacokinetics of ionis SMNRX in infants with spinal muscular atrophy [A study to assess the efficacy, safety, tolerability, and pharmacokinetics of multiple doses of ISIS 396443 delivered intrathecally to patients with infantile‐onset spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT01839656 (first received 22 April 2013). [CTG: NCT01839656; IONIS SMNRx 396443 ‐ CS3A] ">Finkel 2016</a>; <a href="./references#CD006281-bbs2-0017" title="NCT02594124 . An open‐label study (SHINE) for patients with spinal muscular atrophy (sma) who participated in studies with IONIS‐SMNRX [An open‐label extension study for patients with spinal muscular atrophy who previously participated in investigational studies of ISIS 396443]. clinicaltrials.gov/show/NCT02594124 (first received 30 October 2015). [CTG: NCT02594124; EudraCT: EUCTR2015‐001870‐16‐DE; Sponsor's Protocol Code Number: ISIS 396443‐CS11 ] ">SHINE 2015</a>), or RNA‐degradation inhibitors (<a href="./references#CD006281-bbs2-0052" title="ButchbachME , SinghJ , ThorsteinsdottirM , SaievaL , SlominskiE , ThurmondJ , et al. Effects of 2,4‐diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Human Molecular Genetics2010;19(3):454‐67. ">Butchbach 2010</a>; <a href="./references#CD006281-bbs2-0081" title="GogliottiRG , CardonaH , SinghJ , BailS , EmeryC , KuntzN , et al. The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Human Molecular Genetics2013;22(20):4048‐101. ">Gogliotti 2013</a>; <a href="./references#CD006281-bbs2-0190" title="VanMeerbekeJP , GibbsRM , PlastererHL , MiaoW , FengZ , LinMY , et al. The DcpS inhibitor RG3039 improves motor function in SMA mice. Human Molecular Genetics2013;22(20):4074‐83. ">Van Meerbeke 2013</a>), and compounds that replace the <i>SMN1</i> gene have started (<a href="./references#CD006281-bbs2-0011" title="MendellJR , Al‐ZaidyS , ShellR , ArnoldWD , Rodino‐KlapacL , KisselJT , et al. Gene therapy for spinal muscular atrophy type 1 shows potential to improve survival and motor functional outcomes. Molecular Therapy2016;24(Suppl 1):S190. [EMBASE: 72276590; WOS:000375264200475] MendellJR , Al‐ZaidyS , ShellR , ArnoldWD , Rodino‐KlapacLR , PriorTW , et al. Gene‐Replacement Therapy for Spinal Muscular Atrophy. New England Journal of Medicine2017;377(18):1713‐22. NCT02122952 . Gene transfer clinical trial for spinal muscular atrophy type 1 [Phase I gene transfer clinical trial for spinal muscular atrophy type 1 delivering AVXS‐101]. www.clinicaltrial.gov/show/NCT0122952 (first received 23 April 2014). [CTG: NCT02122952; AVXS‐101‐CL‐101] SprouleD , Al‐ZaidyS , ShellR , ArnoldD , Rodino‐KlapacL , KisselJ , et al. Interim safety, efficacy and achievement of developmental milestones in this phase 1, first‐in‐human study of the systemic delivery of AVXS‐101, an AAV9‐mediated gene therapy for children with spinal muscular atrophy (SMA) type 1. Annals of Neurology2016;80(Suppl 20):S368. ">Mendell 2017</a>). </p> <p>Drugs that have been tested in open and uncontrolled studies of children with SMA type I are riluzole (<a href="./references#CD006281-bbs2-0025" title="AbbaraC , EstournetB , LacomblezL , LelièvreB , OuslimaniA , LehmannB , et al. Riluzole pharmacokinetics in young patients with spinal muscular atrophy. British Journal of Clinical Pharmacology2011;71(3):403‐10. ">Abbara 2011</a>; <a href="./references#CD006281-bbs2-0035" title="ASIRI‐ NCT00774423 . Study to evaluate the efficacy of riluzole in children and young adults with spinal muscular atrophy (SMA) (ASIRI) [Multicentric, randomized, double‐blind study versus placebo, with two parallel groups treated to evaluate the efficacy and the tolerance of riluzole in children and young adults (6 to 20 years of age) with SMA. (Type II and Type III)]. www.clinicaltrials.gov/show/NCT00774423 (first received 16 October 2008). [NCT00774423; P040904] ">ASIRI 2008</a>), valproate (<a href="./references#CD006281-bbs2-0004" title="KrosschellKJ , KisselJT , TownsendEL , SimeoneSD , ZhangRZ , ReynaSP , et al. Project Cure SMA Investigator's Network. Clinical trial of L‐Carnitine and valproic acid in spinal muscular atrophy type I. Muscle &amp; Nerve2018;57(2):193‐9. [CTG: NCT00661453; 25409 IND 79276] ">CARNIVAL Type I 2008</a>; <a href="./references#CD006281-bbs2-0006" title="ConceicaoE , SilvaT , UmbertineR , Maria JoaquinaD . Analysis of motor skill acquisition among children with type I spinal muscular atrophy submitted to medication with valproic acid. Amyotrophic Lateral Sclerosis2010;11(Suppl 1):63‐71. ">Conceicao 2010</a>; <a href="./references#CD006281-bbs2-0018" title="SMART01 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy. dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRS06/JMACTRS06.aspx?seqno=4602(first received July 2014). [JPRN‐SMA‐IIA00190] ">SMART01</a>; <a href="./references#CD006281-bbs2-0019" title="SwobodaKJ , ScottCB , ReynaSP , PriorTW , LaSalleB , SorensonSL , et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One2009;4(5):e5268. [PUBMED: 19440247] ">Swoboda 2009</a>; <a href="./references#CD006281-bbs2-0024" title="SMART02 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy: confirmatory trial (SMART02). dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRS06/JMACTRS06.aspx?seqno=5544(first received January 2016). [27‐3594; JPRN‐JMA‐IIA00231] ">SMART02 2016</a>), recombinant human ciliary neurotrophic factor (CNTF) (<a href="./references#CD006281-bbs2-0009" title="FranzDN , TudorCA , SamahaFJ . A phase I trial of recombinant human ciliary neurotrophic factor in spinal muscular atrophy. Annals of Neurology1995; Vol. 38, issue 3:546. ">Franz 1995</a>), sodium phenylbutyrate or phenylbutyrate (<a href="./references#CD006281-bbs2-0015" title="NCT00439218 . Clinical trial of sodium phenylbutyrate in children with spinal muscular atrophy type I [Phase I/IIa clinical trial of sodium phenylbutyrate in pediatric subjects with type I spinal muscular atrophy]. clinicaltrials.gov/show/NCT00439218 (first received 22 February 2007). [CTG: NCT00439218; HHSN265200423611C; N01NS42361_NPTUNE02] ">NPTUNE02 2007</a>; <a href="./references#CD006281-bbs2-0176" title="STOPSMA‐ NCT00528268 . Study to evaluate sodium phenylbutyrate in pre‐symptomatic infants with spinal muscular atrophy (STOPSMA) [Prospective phase I/II study to evaluate effects of sodium phenylbutyrate in pre‐symptomatic infants with spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT00528268 (first received 10 September 2007). [1R01HD054599‐01; 22183; NCT00528268] ">STOPSMA 2007</a>), hydroxyurea (<a href="./references#CD006281-bbs2-0005" title="ChangJG , TsaiFJ , WangWY , JongYJ . Treatment of spinal muscular atrophy by hydroxyurea. American Journal of Human Genetics2002;71(Suppl 4):2402. ">Chang 2002</a>; <a href="./references#CD006281-bbs2-0022" title="NCT00568698 . A pilot therapeutic trial using hydroxyurea in type I spinal muscular atrophy patients. clinicaltrials.gov/show/NCT00568698 (first received 4 December 2007). [78811; NCT00083746; NCT00568698; SU‐11012007‐783] ">NCT00568698</a>), SMN2 antisense oligonucleotides (<a href="./references#CD006281-bbs2-0001" title="FinkelRS , MercuriE , DarrasBT , ConnollyAM , KuntzNL , KirschnerJ , et al. Nusinersen versus sham control in infantile‐onset spinal muscular atrophy. New England Journal of Medicine2017;377(18):1723‐32. NCT02193074 . A study to assess the efficacy and safety of IONIS‐SMN rx in infants with spinal muscular atrophy [A phase 3, randomized, double‐blind, sham‐procedure controlled study to assess the clinical efficacy and safety of IONIS 396443 administered intrathecally in patients with infantile‐onset spinal muscular atrophy]. clinicaltrials.gov/show/NCT02193074 (first received 14 July 2014). [IONIS 396443‐CS3B ; NCT02193074] ">Finkel 2017 (ENDEAR)</a>; <a href="./references#CD006281-bbs2-0007" title="FinkelR , ChiribogaC , VajsarJ , DayJ , MontesJ , DeVivoD , et al. Interim results of a phase 2 clinical study of nusinersen (ISIS‐SMNRx) in patients with infantile‐onset spinal muscular atrophy. Annals of Neurology2016;80(Suppl 20):S371‐2. FinkelRS , ChiribogaCA , VajsarJ , DayJW , MontesJ , DeVivoDC , et al. Treatment of infantile‐onset spinal muscular atrophy with nusinersen: a phase 2, open‐label, dose‐escalation study. Lancet2016;388(10063):3017‐26. NCT01839656 . A study to assess the safety and pharmacokinetics of ionis SMNRX in infants with spinal muscular atrophy [A study to assess the efficacy, safety, tolerability, and pharmacokinetics of multiple doses of ISIS 396443 delivered intrathecally to patients with infantile‐onset spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT01839656 (first received 22 April 2013). [CTG: NCT01839656; IONIS SMNRx 396443 ‐ CS3A] ">Finkel 2016</a>; <a href="./references#CD006281-bbs2-0017" title="NCT02594124 . An open‐label study (SHINE) for patients with spinal muscular atrophy (sma) who participated in studies with IONIS‐SMNRX [An open‐label extension study for patients with spinal muscular atrophy who previously participated in investigational studies of ISIS 396443]. clinicaltrials.gov/show/NCT02594124 (first received 30 October 2015). [CTG: NCT02594124; EudraCT: EUCTR2015‐001870‐16‐DE; Sponsor's Protocol Code Number: ISIS 396443‐CS11 ] ">SHINE 2015</a>; <a href="./references#CD006281-bbs2-0023" title="NCT02462759 . A study to assess the safety and tolerability of ISIS 396443 (ISIS SMNRx) in participants with spinal muscular atrophy (SMA). (EMBRACE) [A phase 2, randomized, double‐blind, sham‐procedure controlled study to assess the safety and tolerability and explore the efficacy of ISIS 396443 (BIIB058) administered intrathecally in subjects with spinal muscular atrophy who are not eligible to participate in the clinical studies ISIS 396443‐CS3B or ISIS 396443‐CS4]. clinicaltrials.gov/show/NCT02462759 (first received 14 May 2015). [CTG: NCT02462759; EudraCT : EUCTR2014‐003657‐33‐DE; 232SM202] ">EMBRACE 2015</a>), and small molecules (<a href="./references#CD006281-bbs2-0008" title="NCT02913482 . A study to Investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type1 spinal muscular atrophy (Firefish) [A two part seamless, open‐label, multicenter study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy]. clinicaltrials.gov/show/NCT02913482 (first received 21 September 2016). [ClinicalTrials.go: NCT02913482] ">FIREFISH 2016</a>; <a href="./references#CD006281-bbs2-0012" title="NCT02268552 . An open label study of LMI070 in type 1 spinal muscular atrophy (SMA) [An open label multi‐part first‐in‐human study of oral LMI070 in infants with type 1 spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT02268552 (first received 1 October 2014). [CTG: NCT02268552; Sponsor's Protocol Code Number: CLMI070X2201] ">NCT02268552</a>; <a href="./references#CD006281-bbs2-0021" title="MOONFISH‐ NCT02240355 . A study of RO6885247 in adult and pediatric patients with spinal muscular atrophy (MOONFISH) [A multicenter, randomized, double blind, placebo controlled, multiple dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6885247 following 12 weeks of treatment in adult and pediatric patients with spinal muscular atrophy (MOONFISH)]. clinicaltrials.gov/show/NCT02240355 (first received 11 September 2014). [CTG: NCT02240355; 2014‐002246‐41; BP29420] ">MOONFISH 2015</a>). <i>SMN1</i> gene therapy and stem cell treatment are outside the scope of this review but are also the subject of ongoing trials (see <a href="./appendices#CD006281-sec-0110">Appendix 1</a>; <a href="./references#CD006281-bbs2-0130" title="MendellJR , Al‐ZaidyS , ShellR , ArnoldWD , Rodino‐KlapacL , KisselJT , et al. Gene therapy for spinal muscular atrophy type 1 shows potential to improve survival and motor functional outcomes. Molecular Therapy2016;24(Suppl 1):S190. [WOS:000375264200475] ">Mendell 2016</a>; <a href="./references#CD006281-bbs2-0011" title="MendellJR , Al‐ZaidyS , ShellR , ArnoldWD , Rodino‐KlapacL , KisselJT , et al. Gene therapy for spinal muscular atrophy type 1 shows potential to improve survival and motor functional outcomes. Molecular Therapy2016;24(Suppl 1):S190. [EMBASE: 72276590; WOS:000375264200475] MendellJR , Al‐ZaidyS , ShellR , ArnoldWD , Rodino‐KlapacLR , PriorTW , et al. Gene‐Replacement Therapy for Spinal Muscular Atrophy. New England Journal of Medicine2017;377(18):1713‐22. NCT02122952 . Gene transfer clinical trial for spinal muscular atrophy type 1 [Phase I gene transfer clinical trial for spinal muscular atrophy type 1 delivering AVXS‐101]. www.clinicaltrial.gov/show/NCT0122952 (first received 23 April 2014). [CTG: NCT02122952; AVXS‐101‐CL‐101] SprouleD , Al‐ZaidyS , ShellR , ArnoldD , Rodino‐KlapacL , KisselJ , et al. Interim safety, efficacy and achievement of developmental milestones in this phase 1, first‐in‐human study of the systemic delivery of AVXS‐101, an AAV9‐mediated gene therapy for children with spinal muscular atrophy (SMA) type 1. Annals of Neurology2016;80(Suppl 20):S368. ">Mendell 2017</a> and <a href="./appendices#CD006281-sec-0112">Appendix 2</a>; <a href="./references#CD006281-bbs2-0020" title="VillanovaM , BachJR . Allogeneic mesenchymal stem cell therapy outcomes for three patients with spinal muscular atrophy type 1. American Journal of Physical Medicine &amp; Rehabilitation2015;94(5):410‐5. ">Villanova 2015</a>; <a href="./references#CD006281-bbs2-0013" title="NCT02855112 . Allogeneic adipose derived stem cells for Werdnig Hoffman patients [The effectiveness of allogeneic adipose derived mesenchymal stem cells (ADMSCs) in the phenotypic changes of Werdnig Hoffman patients]. clinicaltrials.gov/show/NCT02855112 (first received 22 July 2016. [CTG: NCT02855112] ">NCT02855112</a>). </p> <p>Below, we describe the working mechanisms and preclinical studies in SMA models of the various drugs tested in trials with patients with SMA type I. Several other compounds have been shown to have an effect on <i>SMN</i> expression in vivo and in vitro SMA studies, but have not (yet) been tested in studies or trials with patients with SMA and are therefore outside the scope of this review (see <a href="./appendices#CD006281-sec-0113">Appendix 3</a>). </p> <section id="CD006281-sec-0026"> <h4 class="title">Antisense oligonucleotides</h4> <p>Antisense oligonucleotides or 'morpholinos', are synthetic strands of nucleic acids which are able to interfere with (stimulate or inhibit) mRNA products of the target DNA sequence. In this way, antisense oligonucleotides can modify potential splice sites and interfere with splicing (<a href="./references#CD006281-bbs2-0156" title="PorenskyPN , BurghesAH . Antisense oligonucleotides for the treatment of spinal muscular atrophy. Human Gene Therapy2013;24(5):489‐98. ">Porensky 2013</a>). Multiple antisense oligonucleotides for the <i>SMN2</i> gene have been developed and investigated (<a href="./references#CD006281-bbs2-0042" title="BogdanikLP , OsborneMA , DavisC , MartinWP , AustinA , RigoF , et al. Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II/III spinal muscular atrophy. Proceedings of the National Academy of Sciences of United States of America2015;112(43):E5863‐72. ">Bogdanik 2015</a>; <a href="./references#CD006281-bbs2-0106" title="KeilJM , SeoJ , HowellMD , HsuWH , SinghRN , DiDonatoCJ . A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy. Molecular Therapy ‐ Nucleic Acids2014;3:e174. ">Keil 2014</a>; <a href="./references#CD006281-bbs2-0145" title="NizzardoM , SimoneC , SalaniS , RueppMD , RizzoF , RuggieriM , et al. Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy Δ7 mouse model phenotype. Clinical Therapeutics2014;36(3):340‐56. ">Nizzardo 2014</a>; <a href="./references#CD006281-bbs2-0149" title="OsmanEY , MillerMR , RobbinsKL , LombardiAM , AtkinsonAK , BrehmAJ , et al. Morpholino antisense oligonucleotides targeting intronic repressor element 1 improve phenotype in SMA mouse models. Human Molecular Genetics2015;23(18):4832‐45. ">Osman 2014</a>; <a href="./references#CD006281-bbs2-0170" title="ShababiM , LorsonCL . Optimization of SMN trans‐splicing through the analysis of SMN introns. Journal Molecular Neuroscience2012;46(3):459‐69. ">Shababi 2012</a>; <a href="./references#CD006281-bbs2-0172" title="SkordisLA , DunckleyMG , YueB , EperonIC , MuntoniF . Bifunctional antisense oligonucleotides provide a trans‐acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proceedings of National Acadamy of Sciences of the United States of AmericaApril 2003;100(7):4114‐9. ">Skordis 2003</a>; <a href="./references#CD006281-bbs2-0174" title="StaropoliJF , LiH , ChunSJ , AllaireN , CullenP , ThaiA , et al. Rescue of gene‐expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7. Genomics2015;105(4):220‐8. ">Staropoli 2015</a>; <a href="./references#CD006281-bbs2-0205" title="ZhouH , JanghraN , MitrpantC , DickinsonRL , AnthonyK , PriceL , et al. A novel morpholino oligomer targeting ISS‐N1 improves rescue of severe spinal muscular atrophy transgenic mice. Human Gene Therapy2013;24(3):331‐42. ">Zhou 2013</a>; <a href="./references#CD006281-bbs2-0206" title="ZhouH , MengJ , MarrosuE , JanghraN , MorganJ , MuntoniF . Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response. Human Molecular Genetics2015;24(22):6265‐77. ">Zhou 2015</a>). The intronic splice silencer in intron 7 of <i>SMN2</i> , called nusinersen (formerly known as SMN Rx 39443 or IONIS SMN Rx or ISIS‐SMN Rx), specifically targets the splice silencer in intron 7 and ensures the inclusion of <i>SMN2</i> exon 7. This results in increased SMN2 full‐length mRNA and protein production (<a href="./references#CD006281-bbs2-0096" title="HuaY , SahashiK , HungG , RigoF , PassiniMA , BennettCF , et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes &amp; Development2010;24(15):1634‐44. ">Hua 2010</a>), and subsequently SMA animal models have shown improved performance and survival (<a href="./references#CD006281-bbs2-0097" title="HuaY , SahashiK , RigoF , HungG , HorevG , BennettCF , et al. Peripheral SMN restoration is essential for long‐term rescue of a severe SMA mouse model. Nature2011;478(7367):123‐6. ">Hua 2011</a>; <a href="./references#CD006281-bbs2-0152" title="PassiniMA , BuJ , RichardsAM , KinnecomC , SardiSP , StanekLM , et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Science Translational Medicine2011;3(72):72ra18. ">Passini 2011</a>). Nusinersen is an intrathecally‐injected therapy. </p> </section> <section id="CD006281-sec-0027"> <h4 class="title">Ciliary neurotrophic factor (CNTF)</h4> <p>CNTF is thought to support the survival of motor neurons, but its working mechanism is unknown (<a href="./references#CD006281-bbs2-0027" title="ALS CNTF Treatment Study Group. A double‐blind placebo‐controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology1996;46(5):1244‐9. ">ACTS 1996</a>; <a href="./references#CD006281-bbs2-0043" title="BongioanniP , RealiC , SogosV . Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD004302.pub2] ">Bongioanni 2004</a>; <a href="./references#CD006281-bbs2-0135" title="MillerRG , PetajanJH , BryanWW , ArmonC , BarohnRJ , GoodpastureJC , et al. A placebo‐controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Annals of Neurology1996;39(2):256‐60. ">Miller 1996</a>). </p> </section> <section id="CD006281-sec-0028"> <h4 class="title">Hydroxyurea</h4> <p>Hydroxyurea is a histone deacetylase inhibitor and a few studies have suggested a therapeutic role for these agents in SMA, as they appeared to activate <i>SMN2</i> expression (<a href="./references#CD006281-bbs2-0063" title="DarrasBT , KangPB . Clinical trials in spinal muscular atrophy. Current Opinion in Pediatrics2007;19(6):675‐9. ">Darras 2007</a>; <a href="./references#CD006281-bbs2-0107" title="KernochanLE , RussoML , WoodlingNS , HuynhTN , AvilaAM , FischbeckKH , et al. The role of histone acetylation in SMN gene expression. Human Molecular Genetics2005;14(9):1171‐82. ">Kernochan 2005</a>; <a href="./references#CD006281-bbs2-0195" title="WirthB , BrichtaL , HahnenE . Spinal muscular atrophy: from gene to therapy. Seminars in Pediatric Neurology2006;13(2):121‐31. ">Wirth 2006</a>). In vitro, hydroxyurea increased <i>SMN2</i> gene expression and production of SMN protein in cultured lymphocytes of SMA patients (<a href="./references#CD006281-bbs2-0083" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. ">Grzeschik 2005</a>; <a href="./references#CD006281-bbs2-0115" title="LiangWC , YuoCY , ChangJG , ChenYC , ChangYF , WangHY , et al. The effect of hydroxyurea in spinal muscular atrophy cells and patients. Journal of the Neurological Sciences2008;268(1‐2):87‐94. ">Liang 2008</a>). </p> </section> <section id="CD006281-sec-0029"> <h4 class="title">Phenylbutyrate</h4> <p>Phenylbutyrate is another histone deacetylase inhibitor. In fibroblast cultures and leucocytes of patients with SMA treated with phenylbutyrate, the drug was able to increase <i>SMN</i> transcript expression (<a href="./references#CD006281-bbs2-0028" title="Also‐RalloE , AliasL , Martinez‐HernandezR , CasellesL , BarceloMJ , BaigetM , et al. Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter‐ and intra‐patient variability. European Journal of Human Genetics2011;19:1059‐65. ">Also‐Rallo 2011</a>; <a href="./references#CD006281-bbs2-0031" title="AndreassiC , AngelozziC , TizianoFD , VitaliT , DeVincenziE , BoninsegnaA , et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. European Journal of Human Genetics2004;12(1):59‐65. ">Andreassi 2004</a>; <a href="./references#CD006281-bbs2-0046" title="BraheC , VitaliT , TizianoFD , AngelozziC , PintoAM , BorgoF , et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. European Journal of Human Genetics2005;13(2):256‐9. ">Brahe 2005</a>). </p> </section> <section id="CD006281-sec-0030"> <h4 class="title">Riluzole</h4> <p>Riluzole is thought to have a neuroprotective effect on the motor neuron by blocking the presynaptic release of glutamate. Glutamate is released after presynaptic depolarisation and if the amino acid is not efficiently cleared it leads to increased levels of free radicals and eventually degeneration of motor neurons (<a href="./references#CD006281-bbs2-0049" title="BrysonHM , FultonB , BenfieldP . Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs1996;52(4):549‐63. ">Bryson 1996</a>; <a href="./references#CD006281-bbs2-0133" title="MerliniL , SolariA , VitaG , BertiniE , MinettiC , MonginiT , et al. Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. Journal of Child Neurology2003;18(8):537‐41. ">Merlini 2003</a>). In a mouse model of SMA, riluzole attenuated the disease progression (<a href="./references#CD006281-bbs2-0084" title="HaddadH , Cifuentes‐DiazC , MiroglioA , RoblotN , JoshiV , MelkiJ . Riluzole attenuates spinal muscular atrophy disease progression in a mouse model. Muscle &amp; Nerve2003;28(4):432‐7. ">Haddad 2003</a>). </p> </section> <section id="CD006281-sec-0031"> <h4 class="title">Small molecules</h4> <section id="CD006281-sec-0032"> <h5 class="title">RO6885247 or RG7800</h5> <p>The small molecule RO6885247/RG7800 selectively modulates <i>SMN2</i> splicing toward the inclusion of exon 7 and thereby stimulates production of full‐length SMN2 messenger RNA. Administration of RO6885247/RG7800 improved and almost rescued motor function and survival of SMA mice (<a href="./references#CD006281-bbs2-0141" title="NaryshkinNA , WeetallM , DakkaA , NarasimhanJ , ZhaoX , FengZ , et al. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science2014;345(6197):688‐93. ">Naryshkin 2014</a>). </p> </section> <section id="CD006281-sec-0033"> <h5 class="title">RO7034067 or RG7916</h5> <p>The small molecule RO7034067/RG7916 modulates <i>SMN2</i> splicing, but exact details on structure and pharmacology are not available. </p> </section> <section id="CD006281-sec-0034"> <h5 class="title">LMI070</h5> <p>LMI070 reportedly modulates <i>SMN2</i> function, but the precise working mechanism of LMI070 is unknown (<a href="./references#CD006281-bbs2-0012" title="NCT02268552 . An open label study of LMI070 in type 1 spinal muscular atrophy (SMA) [An open label multi‐part first‐in‐human study of oral LMI070 in infants with type 1 spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT02268552 (first received 1 October 2014). [CTG: NCT02268552; Sponsor's Protocol Code Number: CLMI070X2201] ">NCT02268552</a>). </p> </section> </section> <section id="CD006281-sec-0035"> <h4 class="title">Valproate</h4> <p>Valproate is a histone deacetylase inhibitor that increases SMN protein in vitro by increasing transcription of <i>SMN2</i> (<a href="./references#CD006281-bbs2-0107" title="KernochanLE , RussoML , WoodlingNS , HuynhTN , AvilaAM , FischbeckKH , et al. The role of histone acetylation in SMN gene expression. Human Molecular Genetics2005;14(9):1171‐82. ">Kernochan 2005</a>; <a href="./references#CD006281-bbs2-0194" title="WeihlCC , ConnollyAM , PestronkA . Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology2006;67(3):500‐1. ">Weihl 2006</a>). It also has an antiglutamatergic effect (<a href="./references#CD006281-bbs2-0108" title="KimJE , KimDS , KwakSE , ChoiHC , SongHK , ChoiSY , et al. Anti‐glutamatergic effect of riluzole: comparison with valproic acid. Neuroscience2007;147(1):136‐45. ">Kim 2007</a>). Valproate has been tested in SMA and has shown positive results on <i>SMN</i> expression in vitro (<a href="./references#CD006281-bbs2-0048" title="BrichtaL , HofmannY , HahnenE , SiebzehnrublFA , RaschkeH , BlumckeI , et al. Valproic acid increases the SMN2 protein level: a well‐known drug as a potential therapy for spinal muscular atrophy. Human Molecular Genetics2003;12(19):2481‐9. ">Brichta 2003</a>; <a href="./references#CD006281-bbs2-0003" title="BrichtaL , HolkerI , HaugK , KlockgetherT , WirthB . In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Annals of Neurology2006;59(6):970‐5. ">Brichta 2006</a>; <a href="./references#CD006281-bbs2-0177" title="SumnerCJ , HuynhTN , MarkowitzJA , PerhacJS , HillB , CoovertDD , et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Annals of Neurology2003;54(5):647‐54. ">Sumner 2003</a>), and in vivo (<a href="./references#CD006281-bbs2-0155" title="PiepersS , CobbenJM , SodaarP , JansenMD , WadmanRI , Meester‐DelverA , et al. Quantification of SMN protein in leucocytes from spinal muscular atrophy patients: effects of treatment with valproic acid. Journal of Neurology, Neurosurgery, and Psychiatry2011;82(8):850‐2. ">Piepers 2011</a>). </p> </section> </section> <section id="CD006281-sec-0036"> <h3 class="title" id="CD006281-sec-0036">Why it is important to do this review</h3> <p>There is no treatment to slow down or cure SMA type I (<a href="./references#CD006281-bbs2-0209" title="BosboomWM , VranckenAF , van denBergLH , WokkeJH , IannacconeST . Drug treatment for spinal muscular atrophy type I. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006281.pub2] ">Bosboom 2009</a>; <a href="./references#CD006281-bbs2-0210" title="WadmanRI , BosboomWM , van denBergLH , WokkeJH , IannacconeST , VranckenAF . Drug treatment for spinal muscular atrophy type I. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD006281.pub3] ">Wadman 2012</a>). </p> <p>Over the past decades, many studies explored various drug treatments in SMA animal models and/or patients with SMA. Currently, there are several drugs and compounds tested in uncontrolled, unblinded and non‐randomised settings, showing possible positive effects on SMA disease course through neuroprotection (e.g. cardiotrophin‐1, creatine, gabapentin, lamotrigine, riluzole), <i>SMN2</i> ‐inducing activity by histone deacetylase inhibitors (e.g. valproate, phenylbutyrate, hydroxyurea), improvement of neuromuscular transmission function (e.g. pyridostigmine), SMN2 RNA modification by antisense oligonucleotides (e.g. nusinersen), genetic restoration of <i>SMN1</i> through viral vectors, improvement of muscle metabolism and strength (e.g. creatine) and other (unknown) factors (e.g. somatotropin, salbutamol, thyrotropin releasing hormone). Overall, these studies show conflicting evidence about their effects on muscle strength, motor function and survival. </p> <p>In the last couple of years the number of studies and trials for drug treatment in SMA has rapidly expanded. Maintaining an up‐to‐date systematic review of the effects of interventions for SMA type I as they emerge is important. </p> <p>This is an update of a review first published in 2009 and updated in 2011. Drug treatment for SMA types II and III is the subject of a separate Cochrane Review (<a href="./references#CD006281-bbs2-0192" title="WadmanRI , van derPolWL , BosboomWMJ , van denBergLH , IannacconeST , VranckenAFJE . Drug treatment for spinal muscular atrophy types II and III. Cochrane Database of Systematic Reviews (in press). [DOI: 10.1002/14651858.CD006282.pub5] ">Wadman 2018</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006281-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006281-sec-0037"></div> <p>To assess the efficacy and safety of any drug therapy designed to slow or arrest progression of spinal muscular atrophy (SMA) type I. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006281-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006281-sec-0038"></div> <section id="CD006281-sec-0039"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006281-sec-0040"> <h4 class="title">Types of studies</h4> <p>All randomised or quasi‐randomised (alternate or other systematic treatment allocation) studies examining the effect of drug treatment designed to slow or arrest disease progression in children with spinal muscular atrophy (SMA) type I. Effects of drug treatment need to be examined compared to placebo or any other proven, efficacious treatment and/or standard of care. We imposed no limitations by language or publication status. </p> </section> <section id="CD006281-sec-0041"> <h4 class="title">Types of participants</h4> <p>Children with SMA type I fulfilling the criteria outlined in <a href="#CD006281-tbl-0006">Table 1</a>. </p> </section> <section id="CD006281-sec-0042"> <h4 class="title">Types of interventions</h4> <p>Any drug treatment, alone or in combination, designed to slow or arrest the progress of the disease compared to placebo, with no restrictions on the route of administration. </p> </section> <section id="CD006281-sec-0043"> <h4 class="title">Types of outcome measures</h4> <p>These are the outcomes of interest within whichever studies are included, and are not part of the criteria for including studies in a review. </p> <section id="CD006281-sec-0044"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD006281-list-0001"> <li> <p>Time from birth until death or full‐time ventilation (a requirement for 16 hours of ventilation per day regardless of whether this is with a tracheostomy, tube or mask) </p> </li> </ul> </p> </section> <section id="CD006281-sec-0045"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD006281-list-0002"> <li> <p>Acquisition of head control, within one year after the onset of treatment</p> </li> <li> <p>Acquisition of the ability to roll, within one year after the onset of treatment</p> </li> <li> <p>Acquisition of the ability to sit, within one year after the onset of treatment</p> </li> <li> <p>Acquisition of the ability to stand, within one year after the onset of treatment</p> </li> <li> <p>Change in motor disability score (e.g. Hammersmith Infant Neurological Examination‐Section 2 (HINE‐2), Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)), as determined by the original study authors </p> </li> <li> <p>Adverse events attributable to treatment, during the whole study period, separated into severe (requiring or lengthening hospitalisation, life‐threatening, or fatal), and others </p> </li> </ul> </p> </section> </section> </section> <section id="CD006281-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006281-sec-0047"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases on 22 October 2018.</p> <p> <ul id="CD006281-list-0003"> <li> <p>The Cochrane Neuromuscular Specialised Register via the Cochrane Register of Studies (CRS‐Web) (22 October 2018: <a href="./appendices#CD006281-sec-0114">Appendix 4</a>). </p> </li> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies (CRS‐Web) (22 October 2018; <a href="./appendices#CD006281-sec-0115">Appendix 5</a>). </p> </li> <li> <p>MEDLINE (1991 to 19 October 2018; <a href="./appendices#CD006281-sec-0116">Appendix 6</a>) </p> </li> <li> <p>Embase (1991 to 19 October 2018; <a href="./appendices#CD006281-sec-0117">Appendix 7</a>). </p> </li> <li> <p>ISI Web of Science proceedings (1991 to October 2018; <a href="./appendices#CD006281-sec-0118">Appendix 8</a>). </p> </li> </ul> </p> <p>We searched the following trials registries in October 2018 to identify additional trials that had not yet been published. </p> <p> <ul id="CD006281-list-0004"> <li> <p>Clinical trials registry of the US National Institute of Health (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; <a href="./appendices#CD006281-sec-0119">Appendix 9</a>). </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP; <a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>; <a href="./appendices#CD006281-sec-0120">Appendix 10</a>). </p> </li> </ul> </p> <p>We limited searches to 1991 onwards, because at that time, genetic analysis of the survival motor neurone 1 (<i>SMN1</i>) gene became widely available and could be used to establish the diagnosis of SMA. </p> </section> <section id="CD006281-sec-0048"> <h4 class="title">Searching other resources</h4> <p>We handsearched relevant cited references, published studies, reviews, textbooks and conference proceedings. Readers are invited to suggest studies, particularly in other languages, which should be considered for inclusion. </p> </section> </section> <section id="CD006281-sec-0049"> <h3 class="title" id="CD006281-sec-0049">Data collection and analysis</h3> <section id="CD006281-sec-0050"> <h4 class="title">Selection of studies</h4> <p>For this updated review, two review authors (RW and AV) independently checked titles and abstracts obtained from literature searches to identify potentially relevant trials for full review. From the full texts, the review authors independently selected the trials that met the selection criteria for inclusion. Review authors were not blinded to the trial author and source institution. The review authors resolved disagreements by reaching consensus. We presented an adapted PRISMA flowchart of study selection (<a href="./references#CD006281-bbs2-0136" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097] ">Moher 2009</a>). </p> </section> <section id="CD006281-sec-0051"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (RW and AV) extracted data independently using a specially designed data extraction form and entered data into Review Manager 5 for analysis (<a href="./references#CD006281-bbs2-0158" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We obtained missing data from the trial authors or pharmaceutical company whenever possible. Disagreement did not occur, but would have been resolved by reaching consensus or with third party adjudication if necessary. </p> <p>If any reports had required translation, the translator would have extracted data directly using a data extraction form, or the review authors would have extracted data from the translation. Where possible a review author would have checked numerical data in the translation against the study report. </p> </section> <section id="CD006281-sec-0052"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The 'Risk of bias' assessment took into account allocation concealment, security of randomisation, intention‐to‐treat analysis, participant blinding (parent blinding), blinding of outcome assessment, incomplete outcome data, selective reporting and 'other bias'. We also looked for explicit inclusion and exclusion criteria, explicit outcome criteria and how studies dealt with baseline differences between treatment groups. We scored each bias item according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> as 'low', 'high' or 'unclear' (<a href="./references#CD006281-bbs2-0093" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration: Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>Statistical considerations involved a trade‐off between bias and precision. We assessed the risk of bias as 'unclear' when too few details were available to make a judgement of ‘high’ or ‘low' risk, when the risk of bias was genuinely unknown despite sufficient information about the conduct of the study, or when an entry was not relevant to a study. </p> <p>Two review authors (RW and AV) graded the risk of bias in included studies independently. In case of disagreement, the review authors reassessed studies and reached agreement by consensus. </p> </section> <section id="CD006281-sec-0053"> <h4 class="title">Measures of treatment effect</h4> <p>We intended to analyse continuous outcomes using mean differences (MDs) and 95% confidence intervals (CIs) and dichotomous outcomes (such as ability to roll, sit or stand and adverse events) using risk ratios (RRs) with 95% CI. We planned to calculate MDs for pooled data if studies were sufficiently comparable. We would have reported standardised mean differences (SMDs) with 95% CIs if studies assessed an outcome using different but comparable scales. We would have used the standard Review Manager generic inverse variance analysis using treatment effect differences with their standard errors if available data had not been sufficiently comparable between studies. We would have re‐expressed SMDs in units on a known scale, or provided a rule of thumb guide to aid interpretation (<a href="./references#CD006281-bbs2-0060" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. 2nd Edition. Routledge, 1988. ">Cohen 1988</a>; <a href="./references#CD006281-bbs2-0093" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration: Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>For time to death or full‐time ventilation, we obtained results from the Kaplan‐Meier survival analyses. </p> </section> <section id="CD006281-sec-0054"> <h4 class="title">Unit of analysis issues</h4> <p>We did not anticipate cluster‐randomised trials, cross‐over trials or multiple observations for the same outcome and anticipated that any included studies would not present these unit of analysis issues. </p> <p>If we had identified multiarm studies, we would have analysed them so as to avoid double‐counting of participants, for example, we would have combined intervention groups if clinically appropriate, or halved a control group. </p> </section> <section id="CD006281-sec-0055"> <h4 class="title">Dealing with missing data</h4> <p>We carefully evaluated important numerical data such as screened, randomised participants as well as intention‐to‐treat (ITT), and as‐treated and per protocol populations. We investigated attrition rates, e.g. dropouts, losses to follow‐up and withdrawals, and critically appraised issues of missing data and imputation methods (e.g. last observation carried forward). In case of missing outcome data we would have performed an ITT analysis. If standard deviations (SDs) for outcomes had not been reported, we would have imputed these values by assuming the SD of the missing outcome to be the average of the SDs from studies that provided this information. </p> <p>In the event of missing data, we would have contacted the trial investigators to provide additional data. </p> </section> <section id="CD006281-sec-0056"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to identify heterogeneity by visual inspection of the forest plots and a standard Chi² test with a significance level of alpha = 0.1, in view of the low power of this test. </p> <p>We would also have considered the I² statistic, using the rule of thumb thresholds described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006281-bbs2-0093" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration: Available from www.cochrane‐handbook.org. ">Higgins 2011</a>): 0% to 40% might not be important; 30% to 60% may represent moderate heterogeneity; 50% to 90% may represent substantial heterogeneity; and over 75% may indicate considerable heterogeneity. We would have interpreted the importance of I² in relation to the significance of the Chi² test and the magnitude and direction of effects. </p> </section> <section id="CD006281-sec-0057"> <h4 class="title">Assessment of reporting biases</h4> <p>We carried out a thorough search, and searched trials registries for this update to identify completed but unpublished studies and study protocols, to minimise reporting bias. The review included too few studies for the use of funnel plots. </p> </section> <section id="CD006281-sec-0058"> <h4 class="title">Data synthesis</h4> <p>We would have pooled results of studies with the same class of drug treatment. If Chi² analysis showed the data to be heterogeneous, we would have used a random‐effects model with a maximum likelihood estimation, carrying out a sensitivity analysis with a fixed‐effect model (Mantel‐Haenszel RR method). We would have performed formal comparisons of intervention effects according to risk of bias by meta‐regression. The major approach to incorporating 'Risk of bias' assessments would have been to incorporate such studies in the review and restrict meta‐analyses to studies at low (or lower) risk of bias. </p> <p>Where studies included in meta‐analyses had different follow‐up periods we planned to make appropriate adjustments, if necessary using Poisson regression allowing for the aggregate person‐time‐at‐risk in the study groups. </p> <section id="CD006281-sec-0059"> <h5 class="title">'Summary of findings' table</h5> <p>We created 'Summary of findings' tables with the following outcomes.</p> <p> <ul id="CD006281-list-0005"> <li> <p>Time from birth until death or full‐time ventilation (a requirement for 16 hours of ventilation per day regardless of whether this is with a tracheostomy, tube or mask) </p> </li> <li> <p>Acquisition of head control, within one year after the onset of treatment</p> </li> <li> <p>Acquisition of the ability to sit, within one year after the onset of treatment</p> </li> <li> <p>Acquisition of the ability to stand, within one year after the onset of treatment</p> </li> <li> <p>Change in motor disability score, as predefined by the authors of the trial</p> </li> <li> <p>Adverse effects attributable to treatment</p> </li> <li> <p>Severe adverse effects attributable to treatment</p> </li> </ul> </p> <p>According to the Cochrane guidelines, we included a maximum of seven outcomes in the 'Summary of findings' tables (<a href="./references#CD006281-bbs2-0093" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration: Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of a body of evidence (studies that contribute data for the prespecified outcomes). We followed methods and recommendations described in Chapter 11 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006281-bbs2-0167" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011a</a>; <a href="./references#CD006281-bbs2-0168" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions.. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011b</a>), using GRADEproGDT software (<a href="./references#CD006281-bbs2-0082" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed prior to 2 September 2019. Hamilton (ON): McMaster University (developed by Evidence Prime). ">GRADEpro GDT 2015</a>). We justified in footnotes all decisions to downgrade or upgrade the certainty of evidence and made comments to aid readers' understanding of the review where necessary. </p> <p>For future updates, two or more review authors will independently grade the certainty of the evidence in 'Summary of findings' tables and arrive at an agreed assessment by consensus. We will include 'Summary of findings' tables for all comparisons for which any data are available. If comparisons are all of equivalent importance, we will include them all as 'Additional tables'; if one comparison is of greater clinical importance we will choose it for presentation at the start of the review. </p> </section> </section> <section id="CD006281-sec-0060"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In the event of substantial clinical, methodological or statistical heterogeneity, we would not have reported study results as the pooled effect estimate in a meta‐analysis. </p> <p>If we had found heterogeneity, we would have attempted to determine potential reasons for it by examining individual study and subgroup characteristics in sensitivity analyses. </p> <p>We would have performed sensitivity analyses in order to explore the influence of the <i>SMN2</i> copy number (when applicable) on effect sizes and would have used the formal tests for subgroup interactions in Review Manager 5 (<a href="./references#CD006281-bbs2-0158" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> </section> <section id="CD006281-sec-0061"> <h4 class="title">Sensitivity analysis</h4> <p>We would have performed sensitivity analyses as follows, in order to explore the influence of the following factors (if applicable) on effect sizes. We would have restricted the analysis: </p> <p> <ul id="CD006281-list-0006"> <li> <p>by taking into account risk of bias;</p> </li> <li> <p>to outlier studies (very long, very large, very short or very small) to establish the extent to which they dominate the results. </p> </li> </ul> </p> <p>We would also have tested the robustness of the results by repeating the analysis using different measures of effect size (RR, odds ratio (OR) etc.) and different statistical models (fixed‐effect and random‐effects models). </p> <p>We planned formal evaluations of intervention effects according to risk of bias by meta‐regression, as noted above. </p> <section id="CD006281-sec-0062"> <h5 class="title">Non‐randomised evidence</h5> <p>We did not include non‐randomised studies in our final analysis. In the <a href="#CD006281-sec-0086">Discussion</a> section, we reviewed the results from open and uncontrolled studies. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006281-sec-0063" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006281-sec-0063"></div> <section id="CD006281-sec-0064"> <h3 class="title">Description of studies</h3> <p>For this updated review, the number of new references found by the searches were: Cochrane Neuromuscular Specialised Register 37, CENTRAL 90, MEDLINE 351, Embase 123, and ISI Web of Knowledge 277. </p> <p>We named studies with no published data and no acronym after their trial register code (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; <a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>). </p> <section id="CD006281-sec-0065"> <h4 class="title">Results of the search</h4> <p>We identified and assessed the full‐text reports of 24 studies (13 new) for possible inclusion in this updated review (<a href="./references#CD006281-bbs2-0003" title="BrichtaL , HolkerI , HaugK , KlockgetherT , WirthB . In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Annals of Neurology2006;59(6):970‐5. ">Brichta 2006</a>; <a href="./references#CD006281-bbs2-0004" title="KrosschellKJ , KisselJT , TownsendEL , SimeoneSD , ZhangRZ , ReynaSP , et al. Project Cure SMA Investigator's Network. Clinical trial of L‐Carnitine and valproic acid in spinal muscular atrophy type I. Muscle &amp; Nerve2018;57(2):193‐9. [CTG: NCT00661453; 25409 IND 79276] ">CARNIVAL Type I 2008</a>; <a href="./references#CD006281-bbs2-0005" title="ChangJG , TsaiFJ , WangWY , JongYJ . Treatment of spinal muscular atrophy by hydroxyurea. American Journal of Human Genetics2002;71(Suppl 4):2402. ">Chang 2002</a>; <a href="./references#CD006281-bbs2-0006" title="ConceicaoE , SilvaT , UmbertineR , Maria JoaquinaD . Analysis of motor skill acquisition among children with type I spinal muscular atrophy submitted to medication with valproic acid. Amyotrophic Lateral Sclerosis2010;11(Suppl 1):63‐71. ">Conceicao 2010</a>; <a href="./references#CD006281-bbs2-0023" title="NCT02462759 . A study to assess the safety and tolerability of ISIS 396443 (ISIS SMNRx) in participants with spinal muscular atrophy (SMA). (EMBRACE) [A phase 2, randomized, double‐blind, sham‐procedure controlled study to assess the safety and tolerability and explore the efficacy of ISIS 396443 (BIIB058) administered intrathecally in subjects with spinal muscular atrophy who are not eligible to participate in the clinical studies ISIS 396443‐CS3B or ISIS 396443‐CS4]. clinicaltrials.gov/show/NCT02462759 (first received 14 May 2015). [CTG: NCT02462759; EudraCT : EUCTR2014‐003657‐33‐DE; 232SM202] ">EMBRACE 2015</a>; <a href="./references#CD006281-bbs2-0007" title="FinkelR , ChiribogaC , VajsarJ , DayJ , MontesJ , DeVivoD , et al. Interim results of a phase 2 clinical study of nusinersen (ISIS‐SMNRx) in patients with infantile‐onset spinal muscular atrophy. Annals of Neurology2016;80(Suppl 20):S371‐2. FinkelRS , ChiribogaCA , VajsarJ , DayJW , MontesJ , DeVivoDC , et al. Treatment of infantile‐onset spinal muscular atrophy with nusinersen: a phase 2, open‐label, dose‐escalation study. Lancet2016;388(10063):3017‐26. NCT01839656 . A study to assess the safety and pharmacokinetics of ionis SMNRX in infants with spinal muscular atrophy [A study to assess the efficacy, safety, tolerability, and pharmacokinetics of multiple doses of ISIS 396443 delivered intrathecally to patients with infantile‐onset spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT01839656 (first received 22 April 2013). [CTG: NCT01839656; IONIS SMNRx 396443 ‐ CS3A] ">Finkel 2016</a>; <a href="./references#CD006281-bbs2-0001" title="FinkelRS , MercuriE , DarrasBT , ConnollyAM , KuntzNL , KirschnerJ , et al. Nusinersen versus sham control in infantile‐onset spinal muscular atrophy. New England Journal of Medicine2017;377(18):1723‐32. NCT02193074 . A study to assess the efficacy and safety of IONIS‐SMN rx in infants with spinal muscular atrophy [A phase 3, randomized, double‐blind, sham‐procedure controlled study to assess the clinical efficacy and safety of IONIS 396443 administered intrathecally in patients with infantile‐onset spinal muscular atrophy]. clinicaltrials.gov/show/NCT02193074 (first received 14 July 2014). [IONIS 396443‐CS3B ; NCT02193074] ">Finkel 2017 (ENDEAR)</a>; <a href="./references#CD006281-bbs2-0008" title="NCT02913482 . A study to Investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type1 spinal muscular atrophy (Firefish) [A two part seamless, open‐label, multicenter study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy]. clinicaltrials.gov/show/NCT02913482 (first received 21 September 2016). [ClinicalTrials.go: NCT02913482] ">FIREFISH 2016</a>; <a href="./references#CD006281-bbs2-0009" title="FranzDN , TudorCA , SamahaFJ . A phase I trial of recombinant human ciliary neurotrophic factor in spinal muscular atrophy. Annals of Neurology1995; Vol. 38, issue 3:546. ">Franz 1995</a>; <a href="./references#CD006281-bbs2-0010" title="JPRN‐JapicCTI‐163450 . Phase 3 study of K‐828‐SP [Phase 3 study of K‐828‐SP (Long‐term study of sodium valproate in child patients with spinal muscular atrophy)]. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐JapicCTI‐163450(first received November 2016). ">JPRN‐JapicCTI‐163450 2016</a>; <a href="./references#CD006281-bbs2-0011" title="MendellJR , Al‐ZaidyS , ShellR , ArnoldWD , Rodino‐KlapacL , KisselJT , et al. Gene therapy for spinal muscular atrophy type 1 shows potential to improve survival and motor functional outcomes. Molecular Therapy2016;24(Suppl 1):S190. [EMBASE: 72276590; WOS:000375264200475] MendellJR , Al‐ZaidyS , ShellR , ArnoldWD , Rodino‐KlapacLR , PriorTW , et al. Gene‐Replacement Therapy for Spinal Muscular Atrophy. New England Journal of Medicine2017;377(18):1713‐22. NCT02122952 . Gene transfer clinical trial for spinal muscular atrophy type 1 [Phase I gene transfer clinical trial for spinal muscular atrophy type 1 delivering AVXS‐101]. www.clinicaltrial.gov/show/NCT0122952 (first received 23 April 2014). [CTG: NCT02122952; AVXS‐101‐CL‐101] SprouleD , Al‐ZaidyS , ShellR , ArnoldD , Rodino‐KlapacL , KisselJ , et al. Interim safety, efficacy and achievement of developmental milestones in this phase 1, first‐in‐human study of the systemic delivery of AVXS‐101, an AAV9‐mediated gene therapy for children with spinal muscular atrophy (SMA) type 1. Annals of Neurology2016;80(Suppl 20):S368. ">Mendell 2017</a>; <a href="./references#CD006281-bbs2-0021" title="MOONFISH‐ NCT02240355 . A study of RO6885247 in adult and pediatric patients with spinal muscular atrophy (MOONFISH) [A multicenter, randomized, double blind, placebo controlled, multiple dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6885247 following 12 weeks of treatment in adult and pediatric patients with spinal muscular atrophy (MOONFISH)]. clinicaltrials.gov/show/NCT02240355 (first received 11 September 2014). [CTG: NCT02240355; 2014‐002246‐41; BP29420] ">MOONFISH 2015</a>; <a href="./references#CD006281-bbs2-0022" title="NCT00568698 . A pilot therapeutic trial using hydroxyurea in type I spinal muscular atrophy patients. clinicaltrials.gov/show/NCT00568698 (first received 4 December 2007). [78811; NCT00083746; NCT00568698; SU‐11012007‐783] ">NCT00568698</a>; <a href="./references#CD006281-bbs2-0012" title="NCT02268552 . An open label study of LMI070 in type 1 spinal muscular atrophy (SMA) [An open label multi‐part first‐in‐human study of oral LMI070 in infants with type 1 spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT02268552 (first received 1 October 2014). [CTG: NCT02268552; Sponsor's Protocol Code Number: CLMI070X2201] ">NCT02268552</a>; <a href="./references#CD006281-bbs2-0013" title="NCT02855112 . Allogeneic adipose derived stem cells for Werdnig Hoffman patients [The effectiveness of allogeneic adipose derived mesenchymal stem cells (ADMSCs) in the phenotypic changes of Werdnig Hoffman patients]. clinicaltrials.gov/show/NCT02855112 (first received 22 July 2016. [CTG: NCT02855112] ">NCT02855112</a>; <a href="./references#CD006281-bbs2-0014" title="NCT02865109 . To provide access to nusinersen to eligible patients with Infantile‐onset Spinal Muscular Atrophy (SMA) (consistent with Type 1) to address a high‐unmet medical need. clinicaltrials.gov/show/NCT02865109 (first received10 August 2016). ">NCT02865109</a>; <a href="./references#CD006281-bbs2-0015" title="NCT00439218 . Clinical trial of sodium phenylbutyrate in children with spinal muscular atrophy type I [Phase I/IIa clinical trial of sodium phenylbutyrate in pediatric subjects with type I spinal muscular atrophy]. clinicaltrials.gov/show/NCT00439218 (first received 22 February 2007). [CTG: NCT00439218; HHSN265200423611C; N01NS42361_NPTUNE02] ">NPTUNE02 2007</a>; <a href="./references#CD006281-bbs2-0016" title="Prufer de Queiroz Campos AraujoA . Long‐term open salbutamol trial in spinal muscular atrophy. Journal of Neurology2010;257(Suppl 1):S101. ">Prufer de Queiroz Campos Araujo 2010</a>; <a href="./references#CD006281-bbs2-0002" title="RussmanBS , IannacconeST , SamahaFJ . A phase 1 trial of riluzole in spinal muscular atrophy. Archives of Neurology2003;60(11):1601‐3. [PUBMED: 14623733] ">Russman 2003</a>; <a href="./references#CD006281-bbs2-0017" title="NCT02594124 . An open‐label study (SHINE) for patients with spinal muscular atrophy (sma) who participated in studies with IONIS‐SMNRX [An open‐label extension study for patients with spinal muscular atrophy who previously participated in investigational studies of ISIS 396443]. clinicaltrials.gov/show/NCT02594124 (first received 30 October 2015). [CTG: NCT02594124; EudraCT: EUCTR2015‐001870‐16‐DE; Sponsor's Protocol Code Number: ISIS 396443‐CS11 ] ">SHINE 2015</a>; <a href="./references#CD006281-bbs2-0018" title="SMART01 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy. dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRS06/JMACTRS06.aspx?seqno=4602(first received July 2014). [JPRN‐SMA‐IIA00190] ">SMART01</a>; <a href="./references#CD006281-bbs2-0024" title="SMART02 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy: confirmatory trial (SMART02). dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRS06/JMACTRS06.aspx?seqno=5544(first received January 2016). [27‐3594; JPRN‐JMA‐IIA00231] ">SMART02 2016</a>; <a href="./references#CD006281-bbs2-0019" title="SwobodaKJ , ScottCB , ReynaSP , PriorTW , LaSalleB , SorensonSL , et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One2009;4(5):e5268. [PUBMED: 19440247] ">Swoboda 2009</a>; <a href="./references#CD006281-bbs2-0020" title="VillanovaM , BachJR . Allogeneic mesenchymal stem cell therapy outcomes for three patients with spinal muscular atrophy type 1. American Journal of Physical Medicine &amp; Rehabilitation2015;94(5):410‐5. ">Villanova 2015</a>). We excluded 18 studies. </p> <p>We included two studies (<a href="./references#CD006281-bbs2-0001" title="FinkelRS , MercuriE , DarrasBT , ConnollyAM , KuntzNL , KirschnerJ , et al. Nusinersen versus sham control in infantile‐onset spinal muscular atrophy. New England Journal of Medicine2017;377(18):1723‐32. NCT02193074 . A study to assess the efficacy and safety of IONIS‐SMN rx in infants with spinal muscular atrophy [A phase 3, randomized, double‐blind, sham‐procedure controlled study to assess the clinical efficacy and safety of IONIS 396443 administered intrathecally in patients with infantile‐onset spinal muscular atrophy]. clinicaltrials.gov/show/NCT02193074 (first received 14 July 2014). [IONIS 396443‐CS3B ; NCT02193074] ">Finkel 2017 (ENDEAR)</a>; <a href="./references#CD006281-bbs2-0002" title="RussmanBS , IannacconeST , SamahaFJ . A phase 1 trial of riluzole in spinal muscular atrophy. Archives of Neurology2003;60(11):1601‐3. [PUBMED: 14623733] ">Russman 2003</a>). We could not obtain the results of two completed trials, which investigated RO6885247 and hydroxyurea (<a href="./references#CD006281-bbs2-0021" title="MOONFISH‐ NCT02240355 . A study of RO6885247 in adult and pediatric patients with spinal muscular atrophy (MOONFISH) [A multicenter, randomized, double blind, placebo controlled, multiple dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6885247 following 12 weeks of treatment in adult and pediatric patients with spinal muscular atrophy (MOONFISH)]. clinicaltrials.gov/show/NCT02240355 (first received 11 September 2014). [CTG: NCT02240355; 2014‐002246‐41; BP29420] ">MOONFISH 2015</a>; <a href="./references#CD006281-bbs2-0022" title="NCT00568698 . A pilot therapeutic trial using hydroxyurea in type I spinal muscular atrophy patients. clinicaltrials.gov/show/NCT00568698 (first received 4 December 2007). [78811; NCT00083746; NCT00568698; SU‐11012007‐783] ">NCT00568698</a>). </p> <p>See <a href="#CD006281-fig-0001">Figure 1</a> for a flow diagram of the study selection process. </p> <div class="figure" id="CD006281-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006281-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD006281-sec-0066"> <h4 class="title">Included studies</h4> <p>Two studies fulfilled the selection criteria (<a href="./references#CD006281-bbs2-0001" title="FinkelRS , MercuriE , DarrasBT , ConnollyAM , KuntzNL , KirschnerJ , et al. Nusinersen versus sham control in infantile‐onset spinal muscular atrophy. New England Journal of Medicine2017;377(18):1723‐32. NCT02193074 . A study to assess the efficacy and safety of IONIS‐SMN rx in infants with spinal muscular atrophy [A phase 3, randomized, double‐blind, sham‐procedure controlled study to assess the clinical efficacy and safety of IONIS 396443 administered intrathecally in patients with infantile‐onset spinal muscular atrophy]. clinicaltrials.gov/show/NCT02193074 (first received 14 July 2014). [IONIS 396443‐CS3B ; NCT02193074] ">Finkel 2017 (ENDEAR)</a>; <a href="./references#CD006281-bbs2-0002" title="RussmanBS , IannacconeST , SamahaFJ . A phase 1 trial of riluzole in spinal muscular atrophy. Archives of Neurology2003;60(11):1601‐3. [PUBMED: 14623733] ">Russman 2003</a>). Details of the studies are shown in <a href="./references#CD006281-sec-0130" title="">Characteristics of included studies</a>. </p> <section id="CD006281-sec-0067"> <h5 class="title">Nusinersen versus sham procedure</h5> <p>This study was a phase III, randomised, double‐blind, sham procedure‐controlled study with nusinersen in infants with spinal muscular atrophy (SMA) with a genetic confirmation of a deletion of <i>SMN1</i> and 2 copies of <i>SMN2.</i> All participants (n = 121) were less than seven months old at the time of inclusion. Randomisation was in a 2:1 ratio (nusinersen:sham procedure). The planned treatment period was 13 months, with a prespecified interim analysis at six months (183 days). </p> <p>Nusinersen was administered intrathecally by a lumbar puncture (at an age‐scaled equivalent dose of 12 mg in 5 mL: 0 to 3 months old, 9.6 mg in 4.0 mL; 3 to 6 months old, 10.3 mg in 4.3 mL; 6 to 12 months old, 10.8 mg in 4.5 mL; 12 to 24 months old, 11.3 mg in 4.7 mL). Participants received their treatment or sham procedure at days 1, 15, 29, and 64, followed by dosing at day 183 and 302. The sham procedure consisted of a small needle prick on the lower back at the location where the lumbar puncture injection is normally made. The needle broke the skin but no lumbar puncture injection or needle insertion occurred. The needle prick was covered with the same bandage that was used to cover the lumbar puncture injection in the treatment group. </p> <p>The primary outcome in the trial was time to death or permanent assisted ventilation (defined as at least 16 hours per day for more than 21 continuous days). The investigators added a second primary outcome, the percentage of motor milestone responders on the Hammersmith Infant Neurological Examination‐Section 2 (HINE‐2), after the results of the phase II trial became available (<a href="./references#CD006281-bbs2-0007" title="FinkelR , ChiribogaC , VajsarJ , DayJ , MontesJ , DeVivoD , et al. Interim results of a phase 2 clinical study of nusinersen (ISIS‐SMNRx) in patients with infantile‐onset spinal muscular atrophy. Annals of Neurology2016;80(Suppl 20):S371‐2. FinkelRS , ChiribogaCA , VajsarJ , DayJW , MontesJ , DeVivoDC , et al. Treatment of infantile‐onset spinal muscular atrophy with nusinersen: a phase 2, open‐label, dose‐escalation study. Lancet2016;388(10063):3017‐26. NCT01839656 . A study to assess the safety and pharmacokinetics of ionis SMNRX in infants with spinal muscular atrophy [A study to assess the efficacy, safety, tolerability, and pharmacokinetics of multiple doses of ISIS 396443 delivered intrathecally to patients with infantile‐onset spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT01839656 (first received 22 April 2013). [CTG: NCT01839656; IONIS SMNRx 396443 ‐ CS3A] ">Finkel 2016</a>). A response on the HINE‐2 was defined as improvement in at least one category (i.e. an increase in the score for head control, rolling, sitting, crawling, standing, or walking of at least 1 point, an increase in the score for kicking of at least 2 points, or achievement of the maximal score for kicking) and more categories with improvement than categories with worsening (i.e. a decrease was defined as at least 1 point decrease in the score for head control, rolling, sitting, crawling, standing, or walking and a decrease in the score for kicking was defined as a decrease of at least 2 points). </p> <p>The trial also reported the proportion of responders on the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) (a responder was defined as at least a 4‐point score increase from baseline at day 183, 302, or 394 assessments), overall survival rate, percentage of infants not requiring permanent ventilation, proportion of compound muscle action potential (CMAP) responders (peroneal CMAP amplitude increasing to or maintained at 1 mV or more versus baseline at day 183, 302, or 394 assessments), subgroup analyses of time to death or permanent ventilation in patients with a higher or lower disease duration compared to the median disease duration, and adverse events (see <a href="./references#CD006281-sec-0130" title="">Characteristics of included studies</a>). </p> <p>All participants who had a day 183 visit (78 participants; 51 treated with intrathecal nusinersen and 27 who underwent the sham procedure) were included in the interim analysis of motor milestones (HINE‐2). The study was stopped after the interim analysis showed significant benefit from nusinersen compared to the sham procedure. Participants were at that time invited to attend for a final visit for end of trial assessments at least two weeks after their most recent dose of nusinersen or sham procedure. </p> </section> <section id="CD006281-sec-0068"> <h5 class="title">Oral riluzole versus placebo</h5> <p><a href="./references#CD006281-bbs2-0002" title="RussmanBS , IannacconeST , SamahaFJ . A phase 1 trial of riluzole in spinal muscular atrophy. Archives of Neurology2003;60(11):1601‐3. [PUBMED: 14623733] ">Russman 2003</a> was a randomised, placebo‐controlled study with riluzole in 10 children with SMA type I. The main outcome measure was the occurrence of adverse events and the secondary outcome was mortality, under the assumption that the life expectancy without treatment would be no more than 24 months. All children fulfilled clinical criteria for SMA type I, namely onset before the age of six months, never acquiring the ability to sit independently, and genetic confirmation of the diagnosis of SMA. The study investigators had planned to include 30 children with randomisation in a 2:1 ratio (riluzole:placebo). Unfortunately, support from the pharmaceutical industry was withdrawn when Rhone‐Poulenc was taken over by Aventis. From then on no more children were enrolled in the study and therefore the total number of included children was only 10. </p> </section> </section> <section id="CD006281-sec-0069"> <h4 class="title">Excluded studies</h4> <p>We excluded 18 (13 new) studies because they were not randomised or controlled (<a href="./references#CD006281-bbs2-0003" title="BrichtaL , HolkerI , HaugK , KlockgetherT , WirthB . In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Annals of Neurology2006;59(6):970‐5. ">Brichta 2006</a>; <a href="./references#CD006281-bbs2-0004" title="KrosschellKJ , KisselJT , TownsendEL , SimeoneSD , ZhangRZ , ReynaSP , et al. Project Cure SMA Investigator's Network. Clinical trial of L‐Carnitine and valproic acid in spinal muscular atrophy type I. Muscle &amp; Nerve2018;57(2):193‐9. [CTG: NCT00661453; 25409 IND 79276] ">CARNIVAL Type I 2008</a>; <a href="./references#CD006281-bbs2-0005" title="ChangJG , TsaiFJ , WangWY , JongYJ . Treatment of spinal muscular atrophy by hydroxyurea. American Journal of Human Genetics2002;71(Suppl 4):2402. ">Chang 2002</a>; <a href="./references#CD006281-bbs2-0006" title="ConceicaoE , SilvaT , UmbertineR , Maria JoaquinaD . Analysis of motor skill acquisition among children with type I spinal muscular atrophy submitted to medication with valproic acid. Amyotrophic Lateral Sclerosis2010;11(Suppl 1):63‐71. ">Conceicao 2010</a>; <a href="./references#CD006281-bbs2-0008" title="NCT02913482 . A study to Investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type1 spinal muscular atrophy (Firefish) [A two part seamless, open‐label, multicenter study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy]. clinicaltrials.gov/show/NCT02913482 (first received 21 September 2016). [ClinicalTrials.go: NCT02913482] ">FIREFISH 2016</a>; <a href="./references#CD006281-bbs2-0009" title="FranzDN , TudorCA , SamahaFJ . A phase I trial of recombinant human ciliary neurotrophic factor in spinal muscular atrophy. Annals of Neurology1995; Vol. 38, issue 3:546. ">Franz 1995</a>; <a href="./references#CD006281-bbs2-0010" title="JPRN‐JapicCTI‐163450 . Phase 3 study of K‐828‐SP [Phase 3 study of K‐828‐SP (Long‐term study of sodium valproate in child patients with spinal muscular atrophy)]. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐JapicCTI‐163450(first received November 2016). ">JPRN‐JapicCTI‐163450 2016</a>; <a href="./references#CD006281-bbs2-0007" title="FinkelR , ChiribogaC , VajsarJ , DayJ , MontesJ , DeVivoD , et al. Interim results of a phase 2 clinical study of nusinersen (ISIS‐SMNRx) in patients with infantile‐onset spinal muscular atrophy. Annals of Neurology2016;80(Suppl 20):S371‐2. FinkelRS , ChiribogaCA , VajsarJ , DayJW , MontesJ , DeVivoDC , et al. Treatment of infantile‐onset spinal muscular atrophy with nusinersen: a phase 2, open‐label, dose‐escalation study. Lancet2016;388(10063):3017‐26. NCT01839656 . A study to assess the safety and pharmacokinetics of ionis SMNRX in infants with spinal muscular atrophy [A study to assess the efficacy, safety, tolerability, and pharmacokinetics of multiple doses of ISIS 396443 delivered intrathecally to patients with infantile‐onset spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT01839656 (first received 22 April 2013). [CTG: NCT01839656; IONIS SMNRx 396443 ‐ CS3A] ">Finkel 2016</a>; <a href="./references#CD006281-bbs2-0011" title="MendellJR , Al‐ZaidyS , ShellR , ArnoldWD , Rodino‐KlapacL , KisselJT , et al. Gene therapy for spinal muscular atrophy type 1 shows potential to improve survival and motor functional outcomes. Molecular Therapy2016;24(Suppl 1):S190. [EMBASE: 72276590; WOS:000375264200475] MendellJR , Al‐ZaidyS , ShellR , ArnoldWD , Rodino‐KlapacLR , PriorTW , et al. Gene‐Replacement Therapy for Spinal Muscular Atrophy. New England Journal of Medicine2017;377(18):1713‐22. NCT02122952 . Gene transfer clinical trial for spinal muscular atrophy type 1 [Phase I gene transfer clinical trial for spinal muscular atrophy type 1 delivering AVXS‐101]. www.clinicaltrial.gov/show/NCT0122952 (first received 23 April 2014). [CTG: NCT02122952; AVXS‐101‐CL‐101] SprouleD , Al‐ZaidyS , ShellR , ArnoldD , Rodino‐KlapacL , KisselJ , et al. Interim safety, efficacy and achievement of developmental milestones in this phase 1, first‐in‐human study of the systemic delivery of AVXS‐101, an AAV9‐mediated gene therapy for children with spinal muscular atrophy (SMA) type 1. Annals of Neurology2016;80(Suppl 20):S368. ">Mendell 2017</a>; <a href="./references#CD006281-bbs2-0012" title="NCT02268552 . An open label study of LMI070 in type 1 spinal muscular atrophy (SMA) [An open label multi‐part first‐in‐human study of oral LMI070 in infants with type 1 spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT02268552 (first received 1 October 2014). [CTG: NCT02268552; Sponsor's Protocol Code Number: CLMI070X2201] ">NCT02268552</a>; <a href="./references#CD006281-bbs2-0013" title="NCT02855112 . Allogeneic adipose derived stem cells for Werdnig Hoffman patients [The effectiveness of allogeneic adipose derived mesenchymal stem cells (ADMSCs) in the phenotypic changes of Werdnig Hoffman patients]. clinicaltrials.gov/show/NCT02855112 (first received 22 July 2016. [CTG: NCT02855112] ">NCT02855112</a>; <a href="./references#CD006281-bbs2-0014" title="NCT02865109 . To provide access to nusinersen to eligible patients with Infantile‐onset Spinal Muscular Atrophy (SMA) (consistent with Type 1) to address a high‐unmet medical need. clinicaltrials.gov/show/NCT02865109 (first received10 August 2016). ">NCT02865109</a>; <a href="./references#CD006281-bbs2-0015" title="NCT00439218 . Clinical trial of sodium phenylbutyrate in children with spinal muscular atrophy type I [Phase I/IIa clinical trial of sodium phenylbutyrate in pediatric subjects with type I spinal muscular atrophy]. clinicaltrials.gov/show/NCT00439218 (first received 22 February 2007). [CTG: NCT00439218; HHSN265200423611C; N01NS42361_NPTUNE02] ">NPTUNE02 2007</a>; <a href="./references#CD006281-bbs2-0016" title="Prufer de Queiroz Campos AraujoA . Long‐term open salbutamol trial in spinal muscular atrophy. Journal of Neurology2010;257(Suppl 1):S101. ">Prufer de Queiroz Campos Araujo 2010</a>; <a href="./references#CD006281-bbs2-0017" title="NCT02594124 . An open‐label study (SHINE) for patients with spinal muscular atrophy (sma) who participated in studies with IONIS‐SMNRX [An open‐label extension study for patients with spinal muscular atrophy who previously participated in investigational studies of ISIS 396443]. clinicaltrials.gov/show/NCT02594124 (first received 30 October 2015). [CTG: NCT02594124; EudraCT: EUCTR2015‐001870‐16‐DE; Sponsor's Protocol Code Number: ISIS 396443‐CS11 ] ">SHINE 2015</a>; <a href="./references#CD006281-bbs2-0018" title="SMART01 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy. dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRS06/JMACTRS06.aspx?seqno=4602(first received July 2014). [JPRN‐SMA‐IIA00190] ">SMART01</a>; <a href="./references#CD006281-bbs2-0019" title="SwobodaKJ , ScottCB , ReynaSP , PriorTW , LaSalleB , SorensonSL , et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One2009;4(5):e5268. [PUBMED: 19440247] ">Swoboda 2009</a>; <a href="./references#CD006281-bbs2-0020" title="VillanovaM , BachJR . Allogeneic mesenchymal stem cell therapy outcomes for three patients with spinal muscular atrophy type 1. American Journal of Physical Medicine &amp; Rehabilitation2015;94(5):410‐5. ">Villanova 2015</a>; see <a href="./references#CD006281-sec-0131" title="">Characteristics of excluded studies</a>). </p> <p>Six of these excluded studies were not yet completed at the time of our search but we excluded them because of an open‐label, non‐controlled design (<a href="./references#CD006281-bbs2-0008" title="NCT02913482 . A study to Investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type1 spinal muscular atrophy (Firefish) [A two part seamless, open‐label, multicenter study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy]. clinicaltrials.gov/show/NCT02913482 (first received 21 September 2016). [ClinicalTrials.go: NCT02913482] ">FIREFISH 2016</a>; <a href="./references#CD006281-bbs2-0010" title="JPRN‐JapicCTI‐163450 . Phase 3 study of K‐828‐SP [Phase 3 study of K‐828‐SP (Long‐term study of sodium valproate in child patients with spinal muscular atrophy)]. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐JapicCTI‐163450(first received November 2016). ">JPRN‐JapicCTI‐163450 2016</a>; <a href="./references#CD006281-bbs2-0012" title="NCT02268552 . An open label study of LMI070 in type 1 spinal muscular atrophy (SMA) [An open label multi‐part first‐in‐human study of oral LMI070 in infants with type 1 spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT02268552 (first received 1 October 2014). [CTG: NCT02268552; Sponsor's Protocol Code Number: CLMI070X2201] ">NCT02268552</a>; <a href="./references#CD006281-bbs2-0013" title="NCT02855112 . Allogeneic adipose derived stem cells for Werdnig Hoffman patients [The effectiveness of allogeneic adipose derived mesenchymal stem cells (ADMSCs) in the phenotypic changes of Werdnig Hoffman patients]. clinicaltrials.gov/show/NCT02855112 (first received 22 July 2016. [CTG: NCT02855112] ">NCT02855112</a>; <a href="./references#CD006281-bbs2-0014" title="NCT02865109 . To provide access to nusinersen to eligible patients with Infantile‐onset Spinal Muscular Atrophy (SMA) (consistent with Type 1) to address a high‐unmet medical need. clinicaltrials.gov/show/NCT02865109 (first received10 August 2016). ">NCT02865109</a>; <a href="./references#CD006281-bbs2-0017" title="NCT02594124 . An open‐label study (SHINE) for patients with spinal muscular atrophy (sma) who participated in studies with IONIS‐SMNRX [An open‐label extension study for patients with spinal muscular atrophy who previously participated in investigational studies of ISIS 396443]. clinicaltrials.gov/show/NCT02594124 (first received 30 October 2015). [CTG: NCT02594124; EudraCT: EUCTR2015‐001870‐16‐DE; Sponsor's Protocol Code Number: ISIS 396443‐CS11 ] ">SHINE 2015</a>). Two of the excluded studies were recently completed or terminated and results were pending at the time of writing, but we excluded them because of their non‐randomised study design (<a href="./references#CD006281-bbs2-0015" title="NCT00439218 . Clinical trial of sodium phenylbutyrate in children with spinal muscular atrophy type I [Phase I/IIa clinical trial of sodium phenylbutyrate in pediatric subjects with type I spinal muscular atrophy]. clinicaltrials.gov/show/NCT00439218 (first received 22 February 2007). [CTG: NCT00439218; HHSN265200423611C; N01NS42361_NPTUNE02] ">NPTUNE02 2007</a>; <a href="./references#CD006281-bbs2-0018" title="SMART01 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy. dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRS06/JMACTRS06.aspx?seqno=4602(first received July 2014). [JPRN‐SMA‐IIA00190] ">SMART01</a>). </p> </section> </section> <section id="CD006281-sec-0070"> <h3 class="title">Risk of bias in included studies</h3> <p>The 'Risk of bias' assessments for the included studies of <a href="./references#CD006281-bbs2-0001" title="FinkelRS , MercuriE , DarrasBT , ConnollyAM , KuntzNL , KirschnerJ , et al. Nusinersen versus sham control in infantile‐onset spinal muscular atrophy. New England Journal of Medicine2017;377(18):1723‐32. NCT02193074 . A study to assess the efficacy and safety of IONIS‐SMN rx in infants with spinal muscular atrophy [A phase 3, randomized, double‐blind, sham‐procedure controlled study to assess the clinical efficacy and safety of IONIS 396443 administered intrathecally in patients with infantile‐onset spinal muscular atrophy]. clinicaltrials.gov/show/NCT02193074 (first received 14 July 2014). [IONIS 396443‐CS3B ; NCT02193074] ">Finkel 2017 (ENDEAR)</a> and <a href="./references#CD006281-bbs2-0002" title="RussmanBS , IannacconeST , SamahaFJ . A phase 1 trial of riluzole in spinal muscular atrophy. Archives of Neurology2003;60(11):1601‐3. [PUBMED: 14623733] ">Russman 2003</a> can be seen in the <a href="./references#CD006281-sec-0130" title="">Characteristics of included studies</a> table and <a href="#CD006281-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD006281-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Red (‐) indicates high risk of bias, green (+) indicates low risk of bias and yellow (?) indicates unclear risk of bias." data-id="CD006281-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Red (‐) indicates high risk of bias, green (+) indicates low risk of bias and yellow (?) indicates unclear risk of bias. </p> </div> </div> </div> <p><a href="./references#CD006281-bbs2-0002" title="RussmanBS , IannacconeST , SamahaFJ . A phase 1 trial of riluzole in spinal muscular atrophy. Archives of Neurology2003;60(11):1601‐3. [PUBMED: 14623733] ">Russman 2003</a> was at high risk of bias overall. The trial reached only one‐third of the intended enrolment and there were baseline differences between the treatment groups that may have influenced the results: in the placebo group, the age at onset of symptoms, age at diagnosis and age at enrolment in the study were younger than in the riluzole group. The randomisation method, allocation concealment and blinding of parents and observers were not clear; and we assessed randomisation at high risk of bias because of the baseline imbalance. Diagnostic criteria for SMA type I were adequate. The primary outcome was clear and follow‐up of the 10 included children was complete. </p> <p>The overall risk of bias in <a href="./references#CD006281-bbs2-0001" title="FinkelRS , MercuriE , DarrasBT , ConnollyAM , KuntzNL , KirschnerJ , et al. Nusinersen versus sham control in infantile‐onset spinal muscular atrophy. New England Journal of Medicine2017;377(18):1723‐32. NCT02193074 . A study to assess the efficacy and safety of IONIS‐SMN rx in infants with spinal muscular atrophy [A phase 3, randomized, double‐blind, sham‐procedure controlled study to assess the clinical efficacy and safety of IONIS 396443 administered intrathecally in patients with infantile‐onset spinal muscular atrophy]. clinicaltrials.gov/show/NCT02193074 (first received 14 July 2014). [IONIS 396443‐CS3B ; NCT02193074] ">Finkel 2017 (ENDEAR)</a> was low. Baseline characteristics were slightly different concerning age at time of onset and diagnosis, use of ventilator support, and the presence of respiratory and bulbar problems. However, children in the nusinersen‐treated group had an earlier onset and were more severely affected by respiratory and bulbar problems, and with the final results on the efficacy of nusinersen, these baseline differences seemed not to affect the final results. Allocation concealment and random sequence generation were adequate. Blinding procedures were adequate, including the sham procedure. Data reporting was adequate. </p> </section> <section id="CD006281-sec-0071"> <h3 class="title" id="CD006281-sec-0071">Effects of interventions</h3> <p>See: <a href="./full#CD006281-tbl-0001"><b>Summary of findings for the main comparison</b> Intrathecal injected nusinersen compared to sham procedure for infants with SMA and 2 <i>SMN2</i> copies</a>; <a href="./full#CD006281-tbl-0002"><b>Summary of findings 2</b> Riluzole compared to placebo for children with SMA type I</a> </p> <p>We could not perform a meta‐analysis as the two included trials investigated different drug treatments. Outcomes and study designs also varied (<a href="./references#CD006281-bbs2-0001" title="FinkelRS , MercuriE , DarrasBT , ConnollyAM , KuntzNL , KirschnerJ , et al. Nusinersen versus sham control in infantile‐onset spinal muscular atrophy. New England Journal of Medicine2017;377(18):1723‐32. NCT02193074 . A study to assess the efficacy and safety of IONIS‐SMN rx in infants with spinal muscular atrophy [A phase 3, randomized, double‐blind, sham‐procedure controlled study to assess the clinical efficacy and safety of IONIS 396443 administered intrathecally in patients with infantile‐onset spinal muscular atrophy]. clinicaltrials.gov/show/NCT02193074 (first received 14 July 2014). [IONIS 396443‐CS3B ; NCT02193074] ">Finkel 2017 (ENDEAR)</a>; <a href="./references#CD006281-bbs2-0002" title="RussmanBS , IannacconeST , SamahaFJ . A phase 1 trial of riluzole in spinal muscular atrophy. Archives of Neurology2003;60(11):1601‐3. [PUBMED: 14623733] ">Russman 2003</a>; <a href="#CD006281-tbl-0003">Table 2</a>; <a href="#CD006281-tbl-0004">Table 3</a>). </p> <div class="table" id="CD006281-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Oral riluzole versus placebo (Russman 2003)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Riluzole</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants evaluable for analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants (%) who died during the 12‐month study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (57%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median age at death (months)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Range of ages at death (months)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Among the children who died during the 12‐month study. Three of the seven children treated with riluzole were alive at 30, 48 and 64 months' follow‐up. </p> </div> </div> <div class="table" id="CD006281-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Intrathecally‐injected nusinersen versus sham procedure (Finkel 2017 (ENDEAR))</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nusinersen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sham procedure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hazard ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants randomised and included in time‐to‐event analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants who died or had received permanent (&gt; 16 hours per day) ventilation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (39%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (68%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53 (0.32 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.005</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants evaluable for interim analysis<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51 (63%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 (66%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants achieving motor milestone response on HINE‐2 (interim analysis)<sup>bc</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (41%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.15 (1.46 to 368.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants evaluable in final analysis<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73 (91%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (90%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants who survived until the end of trial<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67 (91%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (68%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.18 to 0.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.004</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants who did not use permanent (&gt; 16 hours per day) assisted ventilation until the end of trial<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 (85%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (76%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.3 to 1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants achieving motor milestone response on HINE‐2 (final analysis)<sup>bc</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (51%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.51 (2.43 to 610.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.010</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants achieving head control<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (22%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.95 (1.04 to 274.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants able to roll over<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (10%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.7 (0.45 to 131.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants able to sit independently<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.68 (0.39 to 115.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants able to stand<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.54 (0.06 to 36.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants with response on the CHOP INTEND<sup>bd</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 (71%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.36 (3.79 to 183.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nusinersen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sham procedure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of adverse events<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77 (96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (98%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.92 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants with adverse events occurring &lt; 72 hours of treatment or sham procedure </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51 (64%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (59%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.81 to 1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants with severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (56%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33 (80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.55 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.004</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Interim analysis included all participants that had a day 183 visit at the time of cut‐off (15 June 2016).<br/> <sup>b</sup>Final analysis was performed on data, including participants fulfilling at least six months of trial enrolment.<br/> <sup>c</sup>Response was defined according to scores on the HINE‐2, which assesses the development of motor function through the achievement of motor milestones; in this trial, the scores accounted for seven of the eight motor milestone categories, excluding voluntary grasp. Infants were considered to have a motor milestone response if they met the following two criteria: improvement in at least one category (i.e. an increase in the score for head control, rolling, sitting, crawling, standing, or walking of ≥ 1 point, an increase in the score for kicking of ≥ 2 points, or achievement of the maximal score for kicking) and more categories with improvement than categories with worsening (i.e. a decrease was defined as ≥ 1 point decrease in the score for head control, rolling, sitting, crawling, standing, or walking and a decrease in the score for kicking was defined as a decrease of ≥ 2 points).<br/> <sup>d</sup> Response was defined as an increase of at least 4 points from baseline in the CHOP INTEND score at the end of trial visit (day 183, 302, or 394).<br/> <sup>e</sup> In case a participant had more than one event, only the event with the highest severity was counted. </p> <p>HINE: Hammersmith Infant Neurological Examination; CHOP INTEND: Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders </p> </div> </div> <p><a href="./references#CD006281-bbs2-0002" title="RussmanBS , IannacconeST , SamahaFJ . A phase 1 trial of riluzole in spinal muscular atrophy. Archives of Neurology2003;60(11):1601‐3. [PUBMED: 14623733] ">Russman 2003</a> did not perform statistical analysis because the trialists had enrolled only 10 of the intended 30 participants before the withdrawal of funding. The results are therefore descriptive (see <a href="#CD006281-tbl-0003">Table 2</a>). </p> <section id="CD006281-sec-0072"> <h4 class="title">Intrathecal nusinersen versus sham injection procedure</h4> <p>Data analysis was performed on different subgroups. The prespecified interim analysis included the 78 infants (51 in the nusinersen group and 27 in the sham procedure group) who had been enrolled for at least six months (183 days). The time‐to‐event analysis included all 121 infants (80 in the nusinersen group and 41 in the sham procedure group) who had undergone randomisation and the assigned procedure at least once. All other end points were tested in the final analysis in 110 patients (73 in the nusinersen group and 37 in the sham procedure group) who had been enrolled at least six months before the last participant's final visit (See <a href="./references#CD006281-sec-0130" title="">Characteristics of included studies</a> tables). </p> <section id="CD006281-sec-0073"> <h5 class="title">Primary outcome measure: time from birth until death or full‐time ventilation</h5> <p>By the time of the final analysis (when follow‐up ranged from 6 months to 13 months), 39% of infants in the nusinersen group and 68% of infants in the sham procedure group had died or required full‐time ventilation (at least 16 hours daily for 21 days or more). The trialists calculated a hazard ratio (HR) with the use of a Cox proportional hazards model that was adjusted for disease duration at screening in each infant: HR 0.53, 95% confidence interval (CI) 0.32 to 0.89; moderate‐certainty evidence. This represents a 47% lower risk of death or full‐time ventilation with nusinersen than with the sham procedure. </p> </section> <section id="CD006281-sec-0074"> <h5 class="title">Secondary outcome measures</h5> <section id="CD006281-sec-0075"> <h6 class="title">Acquisition of the ability to have head control, roll, sit, or stand within one year after the onset of treatment </h6> <p>In the nusinersen‐treated group 16/73 infants (22%) achieved head control (risk ratio (RR) 16.95, 95% CI 1.04 to 274.84), 7/73 infants (10%) achieved the ability to roll over (RR 7.70, 95% CI 0.45 to 131.29), 6/73 infants (8%) achieved the ability to sit independently (RR 6.68, 95% CI 0.39 to 115.38) and 1/73 infants (1%) achieved the ability to stand (RR 1.54, 95% CI 0.06 to 36.92). None of the 37 infants in the sham procedure group achieved any of these milestones (<a href="./references#CD006281-fig-0003" title="">Analysis 1.1</a>; <a href="./references#CD006281-fig-0004" title="">Analysis 1.2</a>; <a href="./references#CD006281-fig-0005" title="">Analysis 1.3</a>; <a href="./references#CD006281-fig-0006" title="">Analysis 1.4</a>). We judged the certainty of evidence to be moderate. </p> </section> <section id="CD006281-sec-0076"> <h6 class="title">Change in motor disability score</h6> <section id="CD006281-sec-0077"> <p><b>Motor milestone response (based on predefined criteria) on the Hammersmith Infant Neurological Examination‐Section 2 (HINE‐2) within one year after the onset of treatment</b></p> <p>The responder analysis on motor milestones in 110 participants showed an improvement on the HINE‐2 (according to the predefined response definition) in 37 (51%) participants treated with nusinersen, while none of the participants treated with the sham procedure reached this endpoint (RR 38.51, 95% CI 2.43 to 610.14; N = 110; moderate‐certainty evidence). </p> </section> <section id="CD006281-sec-0078"> <p><b>Response (based on predefined criteria) on CHOP INTEND within one year after the onset of treatment</b></p> <p>A responder analysis on Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) showed 71% of nusinersen‐treated infants responded versus 3% of sham procedure‐treated infants (RR 26.36, 95% CI 3.79 to 183.18; N = 110; moderate‐certainty evidence). </p> </section> </section> <section id="CD006281-sec-0079"> <h6 class="title">Adverse effects attributable to treatment during the whole study period, separated into severe (requiring or lengthening hospitalisation, life‐threatening, or fatal), and others </h6> <p>Reporting included all infants who were randomised and received at least one dose of nusinersen or sham procedure (N = 121). </p> <p>The proportion of participants experiencing adverse events was similar in the nusinersen group (77/80 participants, 96%) and the control group (40/41 participants, 98%) (RR 0.99, 95% CI 0.92 to 1.05; N = 121; moderate‐certainty evidence). </p> <p>The proportion experiencing adverse events, defined as serious, was slightly lower in the nusinersen group (45/80, 56%) than in the placebo group (33/41, 80%) (RR 0.70, 95% CI 0.55 to 0.89; N = 121; moderate‐certainty evidence). We downgraded the certainty of evidence for any adverse events and serious adverse events because the trial cohort and period were small and are unlikely to have captured uncommon adverse events. Adverse events included urinary and respiratory tract infections, respiratory failure, gastrointestinal disorders, pyrexia, intrathecal procedural complications (pain, swelling, site reactions), electrolyte imbalance, cardiac rhythm disorders, rash, and death. </p> </section> </section> </section> <section id="CD006281-sec-0080"> <h4 class="title">Oral riluzole versus placebo</h4> <section id="CD006281-sec-0081"> <h5 class="title">Primary outcome measure: time from birth until death or full‐time ventilation</h5> <p>In the group treated with riluzole, four of seven (57%) children died during the study at a median age of 17 (range 5 to 25) months (mean age 15.75 months). In the placebo group all three children (100%) died at a median age of eight (range 6 to 13) months (mean age 9 months). Three children treated with riluzole were still alive at the age of 30, 48, and 64 months, which was 23, 39, and 49 months after starting the therapy. These children used bilevel positive airway pressure ventilation (BiPAP) only at night. </p> </section> <section id="CD006281-sec-0082"> <h5 class="title">Secondary outcome measures</h5> <section id="CD006281-sec-0083"> <h6 class="title">Acquisition of the ability to control the head, roll, sit, or stand within one year after the onset of treatment </h6> <p>None of the children in the riluzole or placebo group developed the ability to sit. It is unclear if clinical measurements included the acquisition of the ability to roll. The acquisition of the ability to stand was not included in this study. </p> </section> <section id="CD006281-sec-0084"> <h6 class="title">Change in motor disability score</h6> <p>Not measured.</p> </section> <section id="CD006281-sec-0085"> <h6 class="title">Adverse effects attributable to treatment during the whole study period, separated into severe (requiring or lengthening hospitalisation, life‐threatening, or fatal), and others </h6> <p>There were no adverse side effects in either the riluzole‐treated or the placebo‐treated group. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006281-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006281-sec-0086"></div> <section id="CD006281-sec-0087"> <h3 class="title" id="CD006281-sec-0087">Summary of main results</h3> <p>This review includes two published randomised controlled trials (RCTs) on drug treatment for spinal muscular atrophy (SMA) type I (total of 131 patients) (<a href="./references#CD006281-bbs2-0001" title="FinkelRS , MercuriE , DarrasBT , ConnollyAM , KuntzNL , KirschnerJ , et al. Nusinersen versus sham control in infantile‐onset spinal muscular atrophy. New England Journal of Medicine2017;377(18):1723‐32. NCT02193074 . A study to assess the efficacy and safety of IONIS‐SMN rx in infants with spinal muscular atrophy [A phase 3, randomized, double‐blind, sham‐procedure controlled study to assess the clinical efficacy and safety of IONIS 396443 administered intrathecally in patients with infantile‐onset spinal muscular atrophy]. clinicaltrials.gov/show/NCT02193074 (first received 14 July 2014). [IONIS 396443‐CS3B ; NCT02193074] ">Finkel 2017 (ENDEAR)</a>; <a href="./references#CD006281-bbs2-0002" title="RussmanBS , IannacconeST , SamahaFJ . A phase 1 trial of riluzole in spinal muscular atrophy. Archives of Neurology2003;60(11):1601‐3. [PUBMED: 14623733] ">Russman 2003</a>). The treatments investigated were intrathecally‐injected nusinersen and oral riluzole. </p> <p>Intrathecally‐injected nusinersen was shown to be an effective treatment for the improvement of motor milestone achievement and survival or time to require full‐time ventilation in SMA type I, with moderate‐certainty evidence of improvement on the motor milestone outcome (Hammersmith Infant Neurological Examination‐Section 2 (HINE‐2)) and moderate‐certainty evidence of improvement in survival or time to full‐time ventilation in the treatment group, compared to the sham procedure group (<a href="./references#CD006281-bbs2-0001" title="FinkelRS , MercuriE , DarrasBT , ConnollyAM , KuntzNL , KirschnerJ , et al. Nusinersen versus sham control in infantile‐onset spinal muscular atrophy. New England Journal of Medicine2017;377(18):1723‐32. NCT02193074 . A study to assess the efficacy and safety of IONIS‐SMN rx in infants with spinal muscular atrophy [A phase 3, randomized, double‐blind, sham‐procedure controlled study to assess the clinical efficacy and safety of IONIS 396443 administered intrathecally in patients with infantile‐onset spinal muscular atrophy]. clinicaltrials.gov/show/NCT02193074 (first received 14 July 2014). [IONIS 396443‐CS3B ; NCT02193074] ">Finkel 2017 (ENDEAR)</a>). Risk of bias in this trial was low. </p> <p>Baseline characteristics were slightly different concerning age at time of onset and diagnosis, use of ventilator support and the presence of respiratory and bulbar problems, but these differences might have even underestimated the effect of nusinersen since participants in the nusinersen‐treated group had an earlier onset and were more severely affected by respiratory and bulbar problems. </p> <p>It is uncertain whether oral riluzole has any effect in patients with SMA type I. The certainty of the evidence for all measured outcomes from this study was very low, because the study was too small to detect or rule out an effect, and had serious limitations (<a href="./references#CD006281-bbs2-0002" title="RussmanBS , IannacconeST , SamahaFJ . A phase 1 trial of riluzole in spinal muscular atrophy. Archives of Neurology2003;60(11):1601‐3. [PUBMED: 14623733] ">Russman 2003</a>). The trial was not free of bias because of possible baseline differences, and methods of randomisation and blinding were not described. </p> <p>Four additional RCTs investigating oral RO6885247, oral hydroxyurea, intrathecally‐injected nusinersen and oral valproic acid were either ongoing or completed, but no data for analysis were available at the time of writing and they could not be included in the final assessment (<a href="./references#CD006281-bbs2-0023" title="NCT02462759 . A study to assess the safety and tolerability of ISIS 396443 (ISIS SMNRx) in participants with spinal muscular atrophy (SMA). (EMBRACE) [A phase 2, randomized, double‐blind, sham‐procedure controlled study to assess the safety and tolerability and explore the efficacy of ISIS 396443 (BIIB058) administered intrathecally in subjects with spinal muscular atrophy who are not eligible to participate in the clinical studies ISIS 396443‐CS3B or ISIS 396443‐CS4]. clinicaltrials.gov/show/NCT02462759 (first received 14 May 2015). [CTG: NCT02462759; EudraCT : EUCTR2014‐003657‐33‐DE; 232SM202] ">EMBRACE 2015</a>; <a href="./references#CD006281-bbs2-0021" title="MOONFISH‐ NCT02240355 . A study of RO6885247 in adult and pediatric patients with spinal muscular atrophy (MOONFISH) [A multicenter, randomized, double blind, placebo controlled, multiple dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6885247 following 12 weeks of treatment in adult and pediatric patients with spinal muscular atrophy (MOONFISH)]. clinicaltrials.gov/show/NCT02240355 (first received 11 September 2014). [CTG: NCT02240355; 2014‐002246‐41; BP29420] ">MOONFISH 2015</a>; <a href="./references#CD006281-bbs2-0022" title="NCT00568698 . A pilot therapeutic trial using hydroxyurea in type I spinal muscular atrophy patients. clinicaltrials.gov/show/NCT00568698 (first received 4 December 2007). [78811; NCT00083746; NCT00568698; SU‐11012007‐783] ">NCT00568698</a>; <a href="./references#CD006281-bbs2-0024" title="SMART02 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy: confirmatory trial (SMART02). dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRS06/JMACTRS06.aspx?seqno=5544(first received January 2016). [27‐3594; JPRN‐JMA‐IIA00231] ">SMART02 2016</a>). </p> <section id="CD006281-sec-0088"> <h4 class="title">Evidence from other studies in SMA type I</h4> <p>Drugs that have been tested in open and uncontrolled studies of children with SMA type I are riluzole (<a href="./references#CD006281-bbs2-0025" title="AbbaraC , EstournetB , LacomblezL , LelièvreB , OuslimaniA , LehmannB , et al. Riluzole pharmacokinetics in young patients with spinal muscular atrophy. British Journal of Clinical Pharmacology2011;71(3):403‐10. ">Abbara 2011</a>; <a href="./references#CD006281-bbs2-0035" title="ASIRI‐ NCT00774423 . Study to evaluate the efficacy of riluzole in children and young adults with spinal muscular atrophy (SMA) (ASIRI) [Multicentric, randomized, double‐blind study versus placebo, with two parallel groups treated to evaluate the efficacy and the tolerance of riluzole in children and young adults (6 to 20 years of age) with SMA. (Type II and Type III)]. www.clinicaltrials.gov/show/NCT00774423 (first received 16 October 2008). [NCT00774423; P040904] ">ASIRI 2008</a>), valproate (<a href="./references#CD006281-bbs2-0006" title="ConceicaoE , SilvaT , UmbertineR , Maria JoaquinaD . Analysis of motor skill acquisition among children with type I spinal muscular atrophy submitted to medication with valproic acid. Amyotrophic Lateral Sclerosis2010;11(Suppl 1):63‐71. ">Conceicao 2010</a>; <a href="./references#CD006281-bbs2-0004" title="KrosschellKJ , KisselJT , TownsendEL , SimeoneSD , ZhangRZ , ReynaSP , et al. Project Cure SMA Investigator's Network. Clinical trial of L‐Carnitine and valproic acid in spinal muscular atrophy type I. Muscle &amp; Nerve2018;57(2):193‐9. [CTG: NCT00661453; 25409 IND 79276] ">CARNIVAL Type I 2008</a>; <a href="./references#CD006281-bbs2-0018" title="SMART01 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy. dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRS06/JMACTRS06.aspx?seqno=4602(first received July 2014). [JPRN‐SMA‐IIA00190] ">SMART01</a>; <a href="./references#CD006281-bbs2-0024" title="SMART02 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy: confirmatory trial (SMART02). dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRS06/JMACTRS06.aspx?seqno=5544(first received January 2016). [27‐3594; JPRN‐JMA‐IIA00231] ">SMART02 2016</a>; <a href="./references#CD006281-bbs2-0019" title="SwobodaKJ , ScottCB , ReynaSP , PriorTW , LaSalleB , SorensonSL , et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One2009;4(5):e5268. [PUBMED: 19440247] ">Swoboda 2009</a>), recombinant human ciliary neurotrophic factor (CNTF) (<a href="./references#CD006281-bbs2-0009" title="FranzDN , TudorCA , SamahaFJ . A phase I trial of recombinant human ciliary neurotrophic factor in spinal muscular atrophy. Annals of Neurology1995; Vol. 38, issue 3:546. ">Franz 1995</a>), sodium phenylbutyrate or phenylbutyrate (<a href="./references#CD006281-bbs2-0015" title="NCT00439218 . Clinical trial of sodium phenylbutyrate in children with spinal muscular atrophy type I [Phase I/IIa clinical trial of sodium phenylbutyrate in pediatric subjects with type I spinal muscular atrophy]. clinicaltrials.gov/show/NCT00439218 (first received 22 February 2007). [CTG: NCT00439218; HHSN265200423611C; N01NS42361_NPTUNE02] ">NPTUNE02 2007</a>; <a href="./references#CD006281-bbs2-0176" title="STOPSMA‐ NCT00528268 . Study to evaluate sodium phenylbutyrate in pre‐symptomatic infants with spinal muscular atrophy (STOPSMA) [Prospective phase I/II study to evaluate effects of sodium phenylbutyrate in pre‐symptomatic infants with spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT00528268 (first received 10 September 2007). [1R01HD054599‐01; 22183; NCT00528268] ">STOPSMA 2007</a>), hydroxyurea (<a href="./references#CD006281-bbs2-0005" title="ChangJG , TsaiFJ , WangWY , JongYJ . Treatment of spinal muscular atrophy by hydroxyurea. American Journal of Human Genetics2002;71(Suppl 4):2402. ">Chang 2002</a>; <a href="./references#CD006281-bbs2-0022" title="NCT00568698 . A pilot therapeutic trial using hydroxyurea in type I spinal muscular atrophy patients. clinicaltrials.gov/show/NCT00568698 (first received 4 December 2007). [78811; NCT00083746; NCT00568698; SU‐11012007‐783] ">NCT00568698</a>), SMN2 antisense oligonucleotides (<a href="./references#CD006281-bbs2-0001" title="FinkelRS , MercuriE , DarrasBT , ConnollyAM , KuntzNL , KirschnerJ , et al. Nusinersen versus sham control in infantile‐onset spinal muscular atrophy. New England Journal of Medicine2017;377(18):1723‐32. NCT02193074 . A study to assess the efficacy and safety of IONIS‐SMN rx in infants with spinal muscular atrophy [A phase 3, randomized, double‐blind, sham‐procedure controlled study to assess the clinical efficacy and safety of IONIS 396443 administered intrathecally in patients with infantile‐onset spinal muscular atrophy]. clinicaltrials.gov/show/NCT02193074 (first received 14 July 2014). [IONIS 396443‐CS3B ; NCT02193074] ">Finkel 2017 (ENDEAR)</a>; <a href="./references#CD006281-bbs2-0007" title="FinkelR , ChiribogaC , VajsarJ , DayJ , MontesJ , DeVivoD , et al. Interim results of a phase 2 clinical study of nusinersen (ISIS‐SMNRx) in patients with infantile‐onset spinal muscular atrophy. Annals of Neurology2016;80(Suppl 20):S371‐2. FinkelRS , ChiribogaCA , VajsarJ , DayJW , MontesJ , DeVivoDC , et al. Treatment of infantile‐onset spinal muscular atrophy with nusinersen: a phase 2, open‐label, dose‐escalation study. Lancet2016;388(10063):3017‐26. NCT01839656 . A study to assess the safety and pharmacokinetics of ionis SMNRX in infants with spinal muscular atrophy [A study to assess the efficacy, safety, tolerability, and pharmacokinetics of multiple doses of ISIS 396443 delivered intrathecally to patients with infantile‐onset spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT01839656 (first received 22 April 2013). [CTG: NCT01839656; IONIS SMNRx 396443 ‐ CS3A] ">Finkel 2016</a>; <a href="./references#CD006281-bbs2-0017" title="NCT02594124 . An open‐label study (SHINE) for patients with spinal muscular atrophy (sma) who participated in studies with IONIS‐SMNRX [An open‐label extension study for patients with spinal muscular atrophy who previously participated in investigational studies of ISIS 396443]. clinicaltrials.gov/show/NCT02594124 (first received 30 October 2015). [CTG: NCT02594124; EudraCT: EUCTR2015‐001870‐16‐DE; Sponsor's Protocol Code Number: ISIS 396443‐CS11 ] ">SHINE 2015</a>; <a href="./references#CD006281-bbs2-0023" title="NCT02462759 . A study to assess the safety and tolerability of ISIS 396443 (ISIS SMNRx) in participants with spinal muscular atrophy (SMA). (EMBRACE) [A phase 2, randomized, double‐blind, sham‐procedure controlled study to assess the safety and tolerability and explore the efficacy of ISIS 396443 (BIIB058) administered intrathecally in subjects with spinal muscular atrophy who are not eligible to participate in the clinical studies ISIS 396443‐CS3B or ISIS 396443‐CS4]. clinicaltrials.gov/show/NCT02462759 (first received 14 May 2015). [CTG: NCT02462759; EudraCT : EUCTR2014‐003657‐33‐DE; 232SM202] ">EMBRACE 2015</a>), and small molecules (<a href="./references#CD006281-bbs2-0008" title="NCT02913482 . A study to Investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type1 spinal muscular atrophy (Firefish) [A two part seamless, open‐label, multicenter study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy]. clinicaltrials.gov/show/NCT02913482 (first received 21 September 2016). [ClinicalTrials.go: NCT02913482] ">FIREFISH 2016</a>; <a href="./references#CD006281-bbs2-0021" title="MOONFISH‐ NCT02240355 . A study of RO6885247 in adult and pediatric patients with spinal muscular atrophy (MOONFISH) [A multicenter, randomized, double blind, placebo controlled, multiple dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6885247 following 12 weeks of treatment in adult and pediatric patients with spinal muscular atrophy (MOONFISH)]. clinicaltrials.gov/show/NCT02240355 (first received 11 September 2014). [CTG: NCT02240355; 2014‐002246‐41; BP29420] ">MOONFISH 2015</a>; <a href="./references#CD006281-bbs2-0012" title="NCT02268552 . An open label study of LMI070 in type 1 spinal muscular atrophy (SMA) [An open label multi‐part first‐in‐human study of oral LMI070 in infants with type 1 spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT02268552 (first received 1 October 2014). [CTG: NCT02268552; Sponsor's Protocol Code Number: CLMI070X2201] ">NCT02268552</a>). We here discuss the results of treatment with each of these drugs from non‐randomised studies and trials in participants with SMA, especially type I. Drug treatment in SMA types II and III are the topic of another Cochrane Review (<a href="./references#CD006281-bbs2-0192" title="WadmanRI , van derPolWL , BosboomWMJ , van denBergLH , IannacconeST , VranckenAFJE . Drug treatment for spinal muscular atrophy types II and III. Cochrane Database of Systematic Reviews (in press). [DOI: 10.1002/14651858.CD006282.pub5] ">Wadman 2018</a>). </p> <section id="CD006281-sec-0089"> <h5 class="title">Antisense oligonucleotides</h5> <p>A phase II open‐label, dose‐finding study in participants with SMA type I investigating two different dosages of nusinersen (multiple intrathecal doses 6 mg and/or 12 mg respectively), showed significant improvement in outcomes (including achievement of motor milestones, Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) motor function, compound muscle action potential (CMAP) in two investigated nerves and survival) in the 12 mg treated group compared to natural history data (<a href="./references#CD006281-bbs2-0007" title="FinkelR , ChiribogaC , VajsarJ , DayJ , MontesJ , DeVivoD , et al. Interim results of a phase 2 clinical study of nusinersen (ISIS‐SMNRx) in patients with infantile‐onset spinal muscular atrophy. Annals of Neurology2016;80(Suppl 20):S371‐2. FinkelRS , ChiribogaCA , VajsarJ , DayJW , MontesJ , DeVivoDC , et al. Treatment of infantile‐onset spinal muscular atrophy with nusinersen: a phase 2, open‐label, dose‐escalation study. Lancet2016;388(10063):3017‐26. NCT01839656 . A study to assess the safety and pharmacokinetics of ionis SMNRX in infants with spinal muscular atrophy [A study to assess the efficacy, safety, tolerability, and pharmacokinetics of multiple doses of ISIS 396443 delivered intrathecally to patients with infantile‐onset spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT01839656 (first received 22 April 2013). [CTG: NCT01839656; IONIS SMNRx 396443 ‐ CS3A] ">Finkel 2016</a>). A RCT investigating one dose level of nusinersen compared to a sham procedure is ongoing and includes participants with atypical SMA type I, excluding patients with two <i>SMN2</i> copies and under six months old at onset (<a href="./references#CD006281-bbs2-0023" title="NCT02462759 . A study to assess the safety and tolerability of ISIS 396443 (ISIS SMNRx) in participants with spinal muscular atrophy (SMA). (EMBRACE) [A phase 2, randomized, double‐blind, sham‐procedure controlled study to assess the safety and tolerability and explore the efficacy of ISIS 396443 (BIIB058) administered intrathecally in subjects with spinal muscular atrophy who are not eligible to participate in the clinical studies ISIS 396443‐CS3B or ISIS 396443‐CS4]. clinicaltrials.gov/show/NCT02462759 (first received 14 May 2015). [CTG: NCT02462759; EudraCT : EUCTR2014‐003657‐33‐DE; 232SM202] ">EMBRACE 2015</a>). </p> </section> <section id="CD006281-sec-0090"> <h5 class="title">Histone deacetylase inhibitors</h5> <section id="CD006281-sec-0091"> <h6 class="title">Valproate</h6> <p>Valproate has been tested in various open‐label studies (<a href="./references#CD006281-bbs2-0006" title="ConceicaoE , SilvaT , UmbertineR , Maria JoaquinaD . Analysis of motor skill acquisition among children with type I spinal muscular atrophy submitted to medication with valproic acid. Amyotrophic Lateral Sclerosis2010;11(Suppl 1):63‐71. ">Conceicao 2010</a>; <a href="./references#CD006281-bbs2-0062" title="DarbarIA , PlaggertPG , ResendeMB , ZanotelliE , ReedUC . Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid. BMC Neurology2011;11:36. ">Darbar 2011</a>; <a href="./references#CD006281-bbs2-0109" title="KisselJT , ScottCB , ReynaSP , CrawfordTO , SimardLR , KrosschellKJ , et al. SMA carni‐val trial part II: a prospective, single‐ armed trial of L‐carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS ONE2011;6(7):e21296. ">Kissel 2011</a>; <a href="./references#CD006281-bbs2-0165" title="SaitoT , NurputraDK , HarahapNI , HarahapIS , YamamotoH , MuneshigeE , et al. A study of valproic acid for patients with spinal muscular atrophy. Neurology and Clinical Neuroscience2015;3:49‐57. ">Saito 2014</a>; <a href="./references#CD006281-bbs2-0019" title="SwobodaKJ , ScottCB , ReynaSP , PriorTW , LaSalleB , SorensonSL , et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One2009;4(5):e5268. [PUBMED: 19440247] ">Swoboda 2009</a>; <a href="./references#CD006281-bbs2-0186" title="TsaiLK , YangCC , HwuWL , LiH . Valproic acid treatment in six patients with spinal muscular atrophy. European Journal of Neurology2007;14(12):e8‐9. ">Tsai 2007</a>; <a href="./references#CD006281-bbs2-0194" title="WeihlCC , ConnollyAM , PestronkA . Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology2006;67(3):500‐1. ">Weihl 2006</a>). One retrospective study in 15 infants with SMA type I showed stable motor function over months, suggesting an effect of valproate treatment. However, analysis of effect was done only in five participants who survived the two‐year study period (<a href="./references#CD006281-bbs2-0006" title="ConceicaoE , SilvaT , UmbertineR , Maria JoaquinaD . Analysis of motor skill acquisition among children with type I spinal muscular atrophy submitted to medication with valproic acid. Amyotrophic Lateral Sclerosis2010;11(Suppl 1):63‐71. ">Conceicao 2010</a>). An open‐label, uncontrolled trial in 37 infants with SMA did not show effects on survival or respiratory function after treatment with valproate and L‐carnitine compared to an untreated, matched retrospectively analysed cohort. </p> <p>(<a href="./references#CD006281-bbs2-0004" title="KrosschellKJ , KisselJT , TownsendEL , SimeoneSD , ZhangRZ , ReynaSP , et al. Project Cure SMA Investigator's Network. Clinical trial of L‐Carnitine and valproic acid in spinal muscular atrophy type I. Muscle &amp; Nerve2018;57(2):193‐9. [CTG: NCT00661453; 25409 IND 79276] ">CARNIVAL Type I 2008</a>). One open‐label uncontrolled trial in infants with SMA type I investigating valproate is ongoing (<a href="./references#CD006281-bbs2-0018" title="SMART01 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy. dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRS06/JMACTRS06.aspx?seqno=4602(first received July 2014). [JPRN‐SMA‐IIA00190] ">SMART01</a>). An open‐label trial with valproate in 42 children and adults with SMA types I, II and III showed slight improvement in gross motor function in younger non‐ambulatory type II children and variable responses of the survival motor neurone (SMN) transcripts in blood (<a href="./references#CD006281-bbs2-0019" title="SwobodaKJ , ScottCB , ReynaSP , PriorTW , LaSalleB , SorensonSL , et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One2009;4(5):e5268. [PUBMED: 19440247] ">Swoboda 2009</a>). </p> <p>There are two ongoing studies with valproate in SMA type I: one RCT in children with SMA types I and II aged one to seven years old (<a href="./references#CD006281-bbs2-0024" title="SMART02 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy: confirmatory trial (SMART02). dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRS06/JMACTRS06.aspx?seqno=5544(first received January 2016). [27‐3594; JPRN‐JMA‐IIA00231] ">SMART02 2016</a>), and one open‐label trial of sodium valproate in 16 children with SMA types I, II and III (<a href="./references#CD006281-bbs2-0010" title="JPRN‐JapicCTI‐163450 . Phase 3 study of K‐828‐SP [Phase 3 study of K‐828‐SP (Long‐term study of sodium valproate in child patients with spinal muscular atrophy)]. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐JapicCTI‐163450(first received November 2016). ">JPRN‐JapicCTI‐163450 2016</a>). </p> </section> <section id="CD006281-sec-0092"> <h6 class="title">Hydroxyurea</h6> <p>In an uncontrolled open‐label trial in two participants with SMA type I, five participants with SMA type II and two participants with SMA type III, hydroxyurea showed an improvement in muscle strength without side effects (<a href="./references#CD006281-bbs2-0005" title="ChangJG , TsaiFJ , WangWY , JongYJ . Treatment of spinal muscular atrophy by hydroxyurea. American Journal of Human Genetics2002;71(Suppl 4):2402. ">Chang 2002</a>). </p> </section> <section id="CD006281-sec-0093"> <h6 class="title">Phenylbyturate</h6> <p>A multicentre, open‐label phase I/II trial in children with SMA type I on treatment with multiple dosage levels of phenylbutyrate has been terminated due to extremely slow enrolment (<a href="./references#CD006281-bbs2-0015" title="NCT00439218 . Clinical trial of sodium phenylbutyrate in children with spinal muscular atrophy type I [Phase I/IIa clinical trial of sodium phenylbutyrate in pediatric subjects with type I spinal muscular atrophy]. clinicaltrials.gov/show/NCT00439218 (first received 22 February 2007). [CTG: NCT00439218; HHSN265200423611C; N01NS42361_NPTUNE02] ">NPTUNE02 2007</a>). The results of a trial including 14 presymptomatic infants genetically confirmed to have SMA are pending (<a href="./references#CD006281-bbs2-0176" title="STOPSMA‐ NCT00528268 . Study to evaluate sodium phenylbutyrate in pre‐symptomatic infants with spinal muscular atrophy (STOPSMA) [Prospective phase I/II study to evaluate effects of sodium phenylbutyrate in pre‐symptomatic infants with spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT00528268 (first received 10 September 2007). [1R01HD054599‐01; 22183; NCT00528268] ">STOPSMA 2007</a>). </p> </section> </section> <section id="CD006281-sec-0094"> <h5 class="title">Recombinant ciliary neurotrophic factor</h5> <p>A non‐randomised uncontrolled study on the safety and tolerability of recombinant ciliary neurotrophic factor (CNTF) included 10 children with SMA type I (<a href="./references#CD006281-bbs2-0009" title="FranzDN , TudorCA , SamahaFJ . A phase I trial of recombinant human ciliary neurotrophic factor in spinal muscular atrophy. Annals of Neurology1995; Vol. 38, issue 3:546. ">Franz 1995</a>). Six children died; no change in muscle function and strength was noted and there was no difference in disease course and side effects between placebo and treatment groups. </p> </section> <section id="CD006281-sec-0095"> <h5 class="title">Small molecules</h5> <section id="CD006281-sec-0096"> <h6 class="title">RO6885247 or RG7800</h6> <p>A phase I randomised, double‐blind, placebo‐controlled, multiple‐dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO6885247/RG7800 in patients with SMA types I, II and III started in November 2014, but the trial was terminated in December 2016 for safety reasons (<a href="./references#CD006281-bbs2-0021" title="MOONFISH‐ NCT02240355 . A study of RO6885247 in adult and pediatric patients with spinal muscular atrophy (MOONFISH) [A multicenter, randomized, double blind, placebo controlled, multiple dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6885247 following 12 weeks of treatment in adult and pediatric patients with spinal muscular atrophy (MOONFISH)]. clinicaltrials.gov/show/NCT02240355 (first received 11 September 2014). [CTG: NCT02240355; 2014‐002246‐41; BP29420] ">MOONFISH 2015</a>). </p> </section> <section id="CD006281-sec-0097"> <h6 class="title">RO7034067 or RG7916</h6> <p>An open‐label, dose‐escalating trial with RO7034067 or RG7916, also called risdiplam, in infants with SMA type I is currently ongoing (<a href="./references#CD006281-bbs2-0008" title="NCT02913482 . A study to Investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type1 spinal muscular atrophy (Firefish) [A two part seamless, open‐label, multicenter study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy]. clinicaltrials.gov/show/NCT02913482 (first received 21 September 2016). [ClinicalTrials.go: NCT02913482] ">FIREFISH 2016</a>). An open‐label trial with risdaplam once daily in presymptomatic infants with SMA and two <i>SMN2</i> copies is planned (<a href="./references#CD006281-bbs2-0157" title="NCT03779334 . A study of risdiplam in infants with genetically diagnosed and presymptomatic spinal muscular atrophy (Rainbowfish) [An open‐label study of risdiplam in infants with genetically diagnosed and presymptomatic spinal muscular atrophy]. www.clinicaltrial.gov (first date recieved 18 December 2018). [BN40703 ; NCT03779334] ">RAINBOWFISH</a>). </p> </section> <section id="CD006281-sec-0098"> <h6 class="title">LMI070</h6> <p>A phase I, open‐label study with the small molecule 'LMI070', also called branaplam, has started in patients with SMA type I (<a href="./references#CD006281-bbs2-0012" title="NCT02268552 . An open label study of LMI070 in type 1 spinal muscular atrophy (SMA) [An open label multi‐part first‐in‐human study of oral LMI070 in infants with type 1 spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT02268552 (first received 1 October 2014). [CTG: NCT02268552; Sponsor's Protocol Code Number: CLMI070X2201] ">NCT02268552</a>). </p> </section> </section> <section id="CD006281-sec-0099"> <h5 class="title">Other experimental factors</h5> <p>From studies on coenzyme Q10, lithium carbonate and guanidine hydrochloride, it was not clear on clinical grounds whether the participant population consisted only of patients with <i>SMN1</i> deleted SMA, partially because <i>SMN</i> gene analysis was not possible prior to 1991 (<a href="./references#CD006281-bbs2-0032" title="AngeliniC , MicaglioGF , TrevisanC . Guanidine hydrochloride in infantile and juvenile spinal muscular atrophy. A double blind controlled study. Acta Neurologica1980;2(6):460‐5. ">Angelini 1980</a>; <a href="./references#CD006281-bbs2-0073" title="FolkersK , SimonsenR . Two successful double‐blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochimica et Biophysica Acta1995;1271(1):281‐6. ">Folkers 1995</a>; <a href="./references#CD006281-bbs2-0101" title="Il'inaNA , AntipovaRI , KhokhlovAP . Use of lithium carbonate to treat Kugelberg‐Welander spinal amyotrophy [Primenenie uglekislogo litiia dlia lecheniia spinal'noi amiotrofii Kugel'berga‐Velandera]. Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova1980;80(11):1657‐60. ">Il'ina 1980</a>). Therefore, we have not discussed the therapeutic effects of these drugs. </p> <p>In vitro and animal studies have found several other compounds to have an effect on <i>SMN</i> expression, but they are as yet untested in patients with SMA. They are therefore outside the scoop of this review. See <a href="./appendices#CD006281-sec-0110">Appendix 1</a> for a brief description of these compounds. </p> <p><i>SMN1</i> gene therapies are outside the scope of this review. We have added some information on trials in <a href="./appendices#CD006281-sec-0112">Appendix 2</a> for overall completeness. </p> </section> </section> </section> <section id="CD006281-sec-0100"> <h3 class="title" id="CD006281-sec-0100">Overall completeness and applicability of evidence</h3> <p>We are confident that we identified all clinically relevant trials, as we conducted a comprehensive search of all published literature and clinical trials registers and four of the review authors regularly attend international conferences on SMA. </p> <p>Nusinersen is the first treatment effective in SMA.</p> <p>A major issue in SMA, irrespective of the investigated therapy, is the timing of the treatment in relation to its potential effect. Previous experimental studies suggest that there is a limited window of opportunity to rescue or stabilise motor neuron function in the early or presymptomatic stages of the disease. Two trials are currently investigating the efficacy of treatment in presymptomatic SMA patients (<a href="./references#CD006281-bbs2-0147" title="NCT02386553 . A study of multiple doses of ionis smnrx (ISIS 396443) delivered to infants with genetically diagnosed and presymptomatic spinal muscular atrophy (NURTURE) [An open‐label study to assess the efficacy, safety, tolerability, and pharmacokinetics of multiple doses of IONIS 396443 delivered intrathecally to subjects with genetically diagnosed and presymptomatic spinal muscular atrophy.]. www.clinicaltrials.gov/show/NCT02386553 (first received 27 February 2015). [2014‐002098‐12; 232SM201; NCT02386553] ">NURTURE 2015</a>; <a href="./references#CD006281-bbs2-0176" title="STOPSMA‐ NCT00528268 . Study to evaluate sodium phenylbutyrate in pre‐symptomatic infants with spinal muscular atrophy (STOPSMA) [Prospective phase I/II study to evaluate effects of sodium phenylbutyrate in pre‐symptomatic infants with spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT00528268 (first received 10 September 2007). [1R01HD054599‐01; 22183; NCT00528268] ">STOPSMA 2007</a>). A phase I/II study with phenylbutyrate in presymptomatic infants genetically confirmed to have SMA, and suspected to have SMA type I or II according to family history and <i>SMN2</i> copy number, has been completed and results are pending (<a href="./references#CD006281-bbs2-0176" title="STOPSMA‐ NCT00528268 . Study to evaluate sodium phenylbutyrate in pre‐symptomatic infants with spinal muscular atrophy (STOPSMA) [Prospective phase I/II study to evaluate effects of sodium phenylbutyrate in pre‐symptomatic infants with spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT00528268 (first received 10 September 2007). [1R01HD054599‐01; 22183; NCT00528268] ">STOPSMA 2007</a>). Another trial was recently started with nusinersen treatment in presymptomatic infants with genetically confirmed SMA (<a href="./references#CD006281-bbs2-0147" title="NCT02386553 . A study of multiple doses of ionis smnrx (ISIS 396443) delivered to infants with genetically diagnosed and presymptomatic spinal muscular atrophy (NURTURE) [An open‐label study to assess the efficacy, safety, tolerability, and pharmacokinetics of multiple doses of IONIS 396443 delivered intrathecally to subjects with genetically diagnosed and presymptomatic spinal muscular atrophy.]. www.clinicaltrials.gov/show/NCT02386553 (first received 27 February 2015). [2014‐002098‐12; 232SM201; NCT02386553] ">NURTURE 2015</a>). </p> <p>For future (international) trials it is important that the level of supportive care is explicitly described to avoid baseline differences in the treatment arms, since practice guidelines of supportive care, e.g. pulmonary, nutritional and orthopaedic supportive therapy in children and adults with SMA probably differ between centres and countries (<a href="./references#CD006281-bbs2-0041" title="BladenCL , ThompsonR , JacksonJM , GarlandC , WegelC , AmbrosiniA , et al. Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe. Jounal of Neurology2014;261(1):152‐63. ">Bladen 2014</a>). Global practice guidelines for the clinical care of children and adults with SMA are given in the consensus statement for standard care in SMA (<a href="./references#CD006281-bbs2-0072" title="FinkelRS , MercuriE , MeyerOH , SimondsAK , SchrothMK , GrahamRJ , et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromusculular Disordorders2018;28(3):197‐207. ">Finkel 2018</a>; <a href="./references#CD006281-bbs2-0132" title="MercuriE , FinkelRS , MuntoniF , WirthB , MontesJ , MainM , et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscular Disorders2018;28(2):103‐15. ">Mercuri 2018</a>). </p> <section id="CD006281-sec-0101"> <h4 class="title">Certainty of the evidence</h4> <p>We concluded from the one RCT in 10 infants with SMA type I that there is no evidence for or against efficacy of nine months' treatment with oral riluzole in SMA type I (<a href="./references#CD006281-bbs2-0002" title="RussmanBS , IannacconeST , SamahaFJ . A phase 1 trial of riluzole in spinal muscular atrophy. Archives of Neurology2003;60(11):1601‐3. [PUBMED: 14623733] ">Russman 2003</a>). The included trial was not free of bias because possible baseline differences between intervention and control groups occurred and the methods of randomisation and blinding were not described. We performed an analysis of risk of bias, heterogeneity, imprecision and publication bias using GRADE (<a href="./references#CD006281-bbs2-0036" title="AtkinsD , BestD , BrissPA , EcclesM , Falck‐YtterY , FlottorpS , et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490. ">Atkins 2004</a>). We downgraded the certainty of evidence two levels for imprecision (very small sample size) and one level for study limitations (baseline differences between groups), which meant that our assessment of the certainty of evidence was very low. </p> <p>See <a href="./full#CD006281-tbl-0002">summary of findings Table 2</a>. </p> <p>The study of nusinersen, <a href="./references#CD006281-bbs2-0001" title="FinkelRS , MercuriE , DarrasBT , ConnollyAM , KuntzNL , KirschnerJ , et al. Nusinersen versus sham control in infantile‐onset spinal muscular atrophy. New England Journal of Medicine2017;377(18):1723‐32. NCT02193074 . A study to assess the efficacy and safety of IONIS‐SMN rx in infants with spinal muscular atrophy [A phase 3, randomized, double‐blind, sham‐procedure controlled study to assess the clinical efficacy and safety of IONIS 396443 administered intrathecally in patients with infantile‐onset spinal muscular atrophy]. clinicaltrials.gov/show/NCT02193074 (first received 14 July 2014). [IONIS 396443‐CS3B ; NCT02193074] ">Finkel 2017 (ENDEAR)</a>, was at low risk of bias. A slight baseline imbalance meant that children in the nusinersen‐treated group had an earlier onset and were more severely affected by respiratory and bulbar problems. This baseline imbalance in factors related to respiratory decline would tend to favour the control intervention for this outcome. We downgraded the certainty of evidence on survival and motor milestone responses once to moderate because of the risk of bias from baseline imbalance and imprecision (not sufficient to downgrade once for each). Although the effect of nusinersen is large, there is some degree of uncertainty in the effect estimate arising from imprecision in a single study of this size. We did not further downgrade the motor milestone response evidence for imprecision in spite of very wide CIs. The low event rate in the control group is consistent with the natural history of SMA, and responses represented a large effect. We also downgraded the certainty of adverse event findings because small sample size and short trial periods are unlikely to have captured uncommon adverse events. See <a href="./full#CD006281-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> </section> <section id="CD006281-sec-0102"> <h3 class="title" id="CD006281-sec-0102">Potential biases in the review process</h3> <p>There may be some potential for bias in this review process as we made changes to the protocol. These included additions and deletions to the outcomes, as reported in <a href="#CD006281-sec-0128">Differences between protocol and review</a>. None of these changes were made as a result of the findings of the included studies, but rather to improve the structure of the review. </p> <p>We are confident that we identified all clinically relevant trials, as we conducted a comprehensive search of all published literature and clinical trials registers and four of the review authors regularly attend international conferences on SMA. </p> <p>The results of our review might be biased by publication since the results of two completed trials on hydroxyurea (<a href="./references#CD006281-bbs2-0022" title="NCT00568698 . A pilot therapeutic trial using hydroxyurea in type I spinal muscular atrophy patients. clinicaltrials.gov/show/NCT00568698 (first received 4 December 2007). [78811; NCT00083746; NCT00568698; SU‐11012007‐783] ">NCT00568698</a>), and RO6885247 (<a href="./references#CD006281-bbs2-0021" title="MOONFISH‐ NCT02240355 . A study of RO6885247 in adult and pediatric patients with spinal muscular atrophy (MOONFISH) [A multicenter, randomized, double blind, placebo controlled, multiple dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6885247 following 12 weeks of treatment in adult and pediatric patients with spinal muscular atrophy (MOONFISH)]. clinicaltrials.gov/show/NCT02240355 (first received 11 September 2014). [CTG: NCT02240355; 2014‐002246‐41; BP29420] ">MOONFISH 2015</a>), were not available for analysis and review, and two trials investigating nusinersen (<a href="./references#CD006281-bbs2-0023" title="NCT02462759 . A study to assess the safety and tolerability of ISIS 396443 (ISIS SMNRx) in participants with spinal muscular atrophy (SMA). (EMBRACE) [A phase 2, randomized, double‐blind, sham‐procedure controlled study to assess the safety and tolerability and explore the efficacy of ISIS 396443 (BIIB058) administered intrathecally in subjects with spinal muscular atrophy who are not eligible to participate in the clinical studies ISIS 396443‐CS3B or ISIS 396443‐CS4]. clinicaltrials.gov/show/NCT02462759 (first received 14 May 2015). [CTG: NCT02462759; EudraCT : EUCTR2014‐003657‐33‐DE; 232SM202] ">EMBRACE 2015</a>), and valproic acid (<a href="./references#CD006281-bbs2-0018" title="SMART01 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy. dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRS06/JMACTRS06.aspx?seqno=4602(first received July 2014). [JPRN‐SMA‐IIA00190] ">SMART01</a>), are still ongoing. </p> <p>One of the authors of this review (SI) is participating as investigator of different trials on drug treatment in SMA type I. In the next update of the Cochrane Review on SMA type I, an independent analyst will check the data analysis of these trials to avoid the suggestion of bias. </p> </section> <section id="CD006281-sec-0103"> <h3 class="title" id="CD006281-sec-0103">Agreements and disagreements with other studies or reviews</h3> <p>To the best of our knowledge, there are no other systematic reviews investigating the whole spectrum of drug treatment in SMA type I. Several reviews have also identified and discussed various drug treatments in SMA (<a href="./references#CD006281-bbs2-0029" title="AndertonRS , MastagliaFL . Advances and challenges in developing a therapy for spinal muscular atrophy. Expert Review of Neurotherapeutics2015;15(8):895‐908. ">Anderton 2015</a>; <a href="./references#CD006281-bbs2-0034" title="ArnoldWD , BurghesAHM . Spinal Muscular Atrophy: the development and implementation of potential treatments running head. Annals of Neurology2013;74(3):348‐62. ">Arnold 2013</a>; <a href="./references#CD006281-bbs2-0063" title="DarrasBT , KangPB . Clinical trials in spinal muscular atrophy. Current Opinion in Pediatrics2007;19(6):675‐9. ">Darras 2007</a>; <a href="./references#CD006281-bbs2-0114" title="LeweltA , NewcombTM , SwobodaKJ . New therapeutic approaches to spinal muscular atrophy. Current Neurology and Neuroscience Reports2012;12(1):42‐53. ">Lewelt 2012</a>; <a href="./references#CD006281-bbs2-0146" title="NurputraDK , LaiPS , HarahapNI , MorikawaS , YamamotoT , NishimuraN , et al. Spinal muscular atrophy: from gene discovery to clinical trials. Annals of Human Genetics2013;77(5):435‐63. ">Nurputra 2013</a>; <a href="./references#CD006281-bbs2-0175" title="StavarachiM , ApostolP , TomaM , CimponeriuD , GavrilaL . Spinal muscular atrophy disease: a literature review for therapeutic strategies. Journal of Medicine and LifeJanuary‐March 2010;3(1):3‐9. ">Stavarachi 2007</a>; <a href="./references#CD006281-bbs2-0180" title="SwobodaKJ , KisselJT , CrawfordTO , BrombergMB , AcsadiG , D'AnjouG , et al. Perspectives on clinical trials in spinal muscular atrophy. Journal of Child Neurology2007;22(8):957‐66. ">Swoboda 2007</a>; <a href="./references#CD006281-bbs2-0185" title="TisdaleS , PellizzoniL . Disease mechanisms and therapeutic approaches in spinal muscular atrophy. Journal of Neuroscience2015;35(23):8691‐700. ">Tisdale 2015</a>), with some focusing specifically on preclinical studies (<a href="./references#CD006281-bbs2-0169" title="SeoJ , HowellMD , SinghNN , SinghRN . Spinal muscular atrophy: an update on therapeutic progress. Biochimica Biophysica Acta2013;1832(12):2180‐90. ">Seo 2013</a>), genetic therapies (<a href="./references#CD006281-bbs2-0065" title="DonnellyEM , BoulisNM . Update on gene and stem cell therapy approaches for spinal muscular atrophy. Expert Opinion on Biological Therapy2012;11:1463‐71. ">Donelly 2012</a>; <a href="./references#CD006281-bbs2-0202" title="ZanettaC , NizzardoM , SimoneC , MonguzziE , BresolinN , ComiGP , et al. Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials. Clinical Therapeutics2014;36(1):128‐40. ">Zanetta 2014</a>), solely HDACI therapies (<a href="./references#CD006281-bbs2-0137" title="MohseniJ , Zabidi‐HussinZA , SasongkoTH . Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy. Genetics and Molecular Biololgy2013;36(3):299‐307. ">Mohseni 2013</a>), <i>SMN</i>‐inducing therapies (<a href="./references#CD006281-bbs2-0104" title="KaczmarekA , SchneiderS , WirthB , RiesslandM . Investigational therapies for the treatment of spinal muscular atrophy. Expert Opinion on Investigational Drugs2015;24(7):967‐81. ">Kaczmarek 2015</a>), or small molecule and molecular therapies (<a href="./references#CD006281-bbs2-0202" title="ZanettaC , NizzardoM , SimoneC , MonguzziE , BresolinN , ComiGP , et al. Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials. Clinical Therapeutics2014;36(1):128‐40. ">Zanetta 2014</a>). Our conclusions are in line with other reviews. </p> <p>Although we have tried to give an overview of the efficacy of drug treatment with riluzole, hydroxyurea, valproate, phenylbutyrate, recombinant ciliary neurotrophic factor, SMN2 antisense oligonucleotides and small molecules in SMA (see <a href="#CD006281-sec-0025">Description of the intervention</a> and <a href="#CD006281-sec-0086">Discussion</a>), we did not systematically review non‐randomised and preclinical trials and studies and might have missed potential studies. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006281-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/urn:x-wiley:14651858:media:CD006281:CD006281-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_t/tCD006281-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006281-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/full#CD006281-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006281-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/urn:x-wiley:14651858:media:CD006281:CD006281-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_t/tCD006281-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Red (‐) indicates high risk of bias, green (+) indicates low risk of bias and yellow (?) indicates unclear risk of bias." data-id="CD006281-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Red (‐) indicates high risk of bias, green (+) indicates low risk of bias and yellow (?) indicates unclear risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/full#CD006281-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006281-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/urn:x-wiley:14651858:media:CD006281:CD006281-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_t/tCD006281-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Nusinersen versus placebo, Outcome 1 Acquisition of head control." data-id="CD006281-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Nusinersen versus placebo, Outcome 1 Acquisition of head control.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/references#CD006281-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006281-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/urn:x-wiley:14651858:media:CD006281:CD006281-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_t/tCD006281-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Nusinersen versus placebo, Outcome 2 Acquisition of the ability to sit independently." data-id="CD006281-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Nusinersen versus placebo, Outcome 2 Acquisition of the ability to sit independently. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/references#CD006281-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006281-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/urn:x-wiley:14651858:media:CD006281:CD006281-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_t/tCD006281-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Nusinersen versus placebo, Outcome 3 Acquisition of the ability to stand." data-id="CD006281-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Nusinersen versus placebo, Outcome 3 Acquisition of the ability to stand.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/references#CD006281-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006281-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/urn:x-wiley:14651858:media:CD006281:CD006281-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_t/tCD006281-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Nusinersen versus placebo, Outcome 4 Acquisition of the ability to roll." data-id="CD006281-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Nusinersen versus placebo, Outcome 4 Acquisition of the ability to roll.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/references#CD006281-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006281-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/urn:x-wiley:14651858:media:CD006281:CD006281-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_t/tCD006281-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Nusinersen versus placebo, Outcome 5 Motor milestone response on the Hammersmith Infant Neurological Examination‐Section 2 (HINE‐2) (final analysis)." data-id="CD006281-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Nusinersen versus placebo, Outcome 5 Motor milestone response on the Hammersmith Infant Neurological Examination‐Section 2 (HINE‐2) (final analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/references#CD006281-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006281-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/urn:x-wiley:14651858:media:CD006281:CD006281-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_t/tCD006281-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Nusinersen versus placebo, Outcome 6 Motor milestone response on the Hammersmith Infant Neurological Examination‐Section 2 (HINE‐2) (interim analysis)." data-id="CD006281-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Nusinersen versus placebo, Outcome 6 Motor milestone response on the Hammersmith Infant Neurological Examination‐Section 2 (HINE‐2) (interim analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/references#CD006281-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006281-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/urn:x-wiley:14651858:media:CD006281:CD006281-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_t/tCD006281-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Nusinersen versus placebo, Outcome 7 Response on the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) (final analysis)." data-id="CD006281-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Nusinersen versus placebo, Outcome 7 Response on the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) (final analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/references#CD006281-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006281-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/urn:x-wiley:14651858:media:CD006281:CD006281-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_t/tCD006281-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Nusinersen versus placebo, Outcome 8 Adverse events." data-id="CD006281-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Nusinersen versus placebo, Outcome 8 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/references#CD006281-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006281-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/urn:x-wiley:14651858:media:CD006281:CD006281-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_t/tCD006281-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Nusinersen versus placebo, Outcome 9 Severe adverse events." data-id="CD006281-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Nusinersen versus placebo, Outcome 9 Severe adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/references#CD006281-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/media/CDSR/CD006281/image_n/nCD006281-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006281-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intrathecal injected nusinersen compared to sham procedure for infants with SMA and 2 SMN2 copies</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Intrathecal injected nusinersen compared to sham procedure for infants with SMA and 2 <i>SMN2</i> copies</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> infants with SMA and 2 <i>SMN2</i> copies<br/> <b>Setting:</b> in‐hospital treatment for outpatient clinic<br/> <b>Intervention:</b> intrathecal injected nusinersen<br/> <b>Comparison:</b> sham procedure </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with sham procedure</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with intrathecal injected nusinersen</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Time from birth until death or full‐time ventilation</b><sup>a</sup><br/> Follow‐up: range 6 months to 13 months<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.53</b><br/> (0.32 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>121<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>This represents a 47% lower risk of death or full‐time ventilation with nusinersen than with the sham procedure </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>46 per 100</b><br/> (31 to 64) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acquisition of head control</b> within one year after the onset of treatment<br/> Follow‐up: range 6 months to 13 months<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 of 37 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 of 73 participants in the nusinersen‐treated group achieved head control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 16.95</b> (1.04 to 274.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquisition of the ability to sit</b> within one year after the onset of treatment<br/> Follow‐up: range 6 months to 13 months<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 of 37 participants</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 of 73 participants in the nusinersen‐treated group achieved the ability to sit independently</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 6.68</b> </p> <p>(0.39 to 115.38)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquisition of the ability to stand</b> within one year after the onset of treatment<br/> Follow‐up: range 6 months to 13 months<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 of 37 participants in the sham procedure group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 of 73 participants in the nusinersen‐treated group achieved the ability to stand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.54</b> </p> <p>(0.06 to 36.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Change in motor disability score</b> ‐ response on HINE‐2 within one year after the onset of treatment<sup>e</sup><br/> Follow‐up: range 6 months to 13 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 of 37 participants in the sham procedure group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 of 73 participants in the nusinersen‐treated group showed a motor milestone response on the HINE‐2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 38.51</b> (2.43 to 610.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events attributable to treatment</b> </p> <p>Measured as adverse events (all)<br/> Follow‐up: range 6 months to 13 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.99</b> </p> <p>(0.92 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>121<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Including bleeding risk from thrombocytopenia, renal toxicity, hyponatraemia, reduced growth, rash and possible (cerebral) vasculitis, hepatotoxicity, QTc interval prolongation on electrocardiogram, aspiration, infections, gastrointestinal problems </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>976 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>966 per 1000</b> </p> <p>(898 to 1000)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Severe adverse events attributable to treatment</b> </p> <p>Measured as severe adverse events (all)<br/> Follow‐up: range 6 months to 13 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.70</b> </p> <p>(0.55 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>121<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Including respiratory problems, cardiorespiratory arrest, death, brain injury, hypoxic ischaemic encephalopathy </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>805 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>563 per 1000</b> </p> <p>(443 to 716)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CHOP INTEND</b> : Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders; <b>HINE‐2</b> : Hammersmith Infant Neurological Examination‐Section 2; <b>CI</b> : confidence interval; <b>HR</b> : hazard ratio; <b>RCT</b> : randomised controlled trial; <b>RR</b> : risk ratio; <b>SMA</b>: spinal muscular atrophy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Defined as a requirement for 16 hours of ventilation per day regardless of whether via tracheostomy, tube or mask.<br/> <sup>b</sup>We downgraded the certainty of the evidence once for risk of bias and imprecision (not sufficient to downgrade once for each). A slight baseline imbalance meant that children in the nusinersen‐treated group had an earlier onset and were more severely affected by respiratory and bulbar problems. This baseline imbalance in factors related to respiratory decline would tend to favour the control intervention for this outcome. Although the effect of nusinersen is large, there is some degree of uncertainty in the effect estimate arising from imprecision in a single study of this size.<br/> <sup>c</sup>Based on the final analysis. An interim analysis of motor milestones (HINE‐2) was performed on all participants who had a day 183 visit. The study was then stopped for significant benefit from nusinersen. Final analysis was performed on data including participants fulfilling at least six months of trial enrolment.<br/> <sup>d</sup>We downgraded the certainty of the evidence once for risk of bias and imprecision (not sufficient to downgrade once for each). There was slight baseline imbalance and there is some degree of uncertainty in the effect estimate arising from imprecision in a single study of this size. We did not downgrade the motor milestone outcome results further for imprecision, in spite of wide CI. The absence of events in the control group is consistent with the natural history of SMA type 1 and a response represents a large treatment effect.<br/> <sup>e</sup>Response was defined according to scores on the HINE‐2, which assesses the development of motor function through the achievement of motor milestones; in this trial, the scores accounted for 7 of the 8 motor milestone categories, excluding voluntary grasp. Infants were considered to have a motor milestone response if they met the following two criteria: improvement in at least one category (i.e. an increase in the score for head control, rolling, sitting, crawling, standing, or walking of ≥ 1 point, an increase in the score for kicking of ≥ 2 points, or achievement of the maximal score for kicking) and more categories with improvement than categories with worsening (i.e. a decrease was defined as ≥ 1 point decrease in the score for head control, rolling, sitting, crawling, standing, or walking and a decrease in the score for kicking was defined as a decrease of ≥ 2 points).<br/> <sup>f</sup>We downgraded one level for imprecision because the small sample size and shortened study duration mean that the study is unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Intrathecal injected nusinersen compared to sham procedure for infants with SMA and 2 SMN2 copies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/full#CD006281-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006281-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Riluzole compared to placebo for children with SMA type I</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Riluzole compared to placebo for children with SMA type I</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with SMA type I<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> riluzole<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Impact</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign=""> <p><b>Commments</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time from birth until death or full‐time ventilation</b><br/> Follow‐up: range 1 month to 64 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In the 3 children in the placebo group, the median age at death was 8 months (range 6 to 13 months). 4/7 children treated with riluzole died during the trial, at a median age of 17 months (range 5 to 25 months); the remaining 3 children treated with riluzole were still alive at 30, 48 and 64 months. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acquisition of head control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquisition of the ability to sit</b> <br/> Follow‐up: range 1 month to 64 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>None of the children in the riluzole or the placebo group acquired the ability to sit (follow‐up was extended up to 30 to 64 months in the children treated with riluzole). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquisition of the ability to stand</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in motor disability score</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events attributable to treatment</b><br/> Follow‐up: range 1 month to 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No adverse events occurred in children treated with placebo or riluzole.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Severe adverse events attributable to treatment</b><br/> Follow‐up: range 1 months to 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No adverse events occurred in children treated with placebo or riluzole.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>RCT</b> : randomised controlled trial; <b>SMA</b>: spinal muscular atrophy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the certainty of the evidence three levels: twice for serious imprecision, because of the small cohort, and once for risk of bias as there were baseline differences between treatment and control groups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Riluzole compared to placebo for children with SMA type I</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/full#CD006281-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006281-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Oral riluzole versus placebo (Russman 2003)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Riluzole</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants evaluable for analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants (%) who died during the 12‐month study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (57%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (100%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median age at death (months)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Range of ages at death (months)*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>*Among the children who died during the 12‐month study. Three of the seven children treated with riluzole were alive at 30, 48 and 64 months' follow‐up. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Oral riluzole versus placebo (Russman 2003)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/full#CD006281-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006281-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Intrathecally‐injected nusinersen versus sham procedure (Finkel 2017 (ENDEAR))</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nusinersen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sham procedure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Hazard ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of participants randomised and included in time‐to‐event analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants who died or had received permanent (&gt; 16 hours per day) ventilation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (39%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (68%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53 (0.32 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.005</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants evaluable for interim analysis<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51 (63%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 (66%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants achieving motor milestone response on HINE‐2 (interim analysis)<sup>bc</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (41%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.15 (1.46 to 368.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants evaluable in final analysis<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73 (91%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (90%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants who survived until the end of trial<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67 (91%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (68%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.37 (0.18 to 0.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.004</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants who did not use permanent (&gt; 16 hours per day) assisted ventilation until the end of trial<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 (85%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (76%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.66 (0.3 to 1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants achieving motor milestone response on HINE‐2 (final analysis)<sup>bc</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (51%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.51 (2.43 to 610.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.010</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants achieving head control<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (22%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.95 (1.04 to 274.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants able to roll over<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (10%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.7 (0.45 to 131.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants able to sit independently<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.68 (0.39 to 115.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants able to stand<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.54 (0.06 to 36.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants with response on the CHOP INTEND<sup>bd</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 (71%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.36 (3.79 to 183.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt;0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nusinersen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sham procedure</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of adverse events<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77 (96%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (98%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 (0.92 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants with adverse events occurring &lt; 72 hours of treatment or sham procedure </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51 (64%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (59%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 (0.81 to 1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number (%) of participants with severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (56%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33 (80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70 (0.55 to 0.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.004</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Interim analysis included all participants that had a day 183 visit at the time of cut‐off (15 June 2016).<br/> <sup>b</sup>Final analysis was performed on data, including participants fulfilling at least six months of trial enrolment.<br/> <sup>c</sup>Response was defined according to scores on the HINE‐2, which assesses the development of motor function through the achievement of motor milestones; in this trial, the scores accounted for seven of the eight motor milestone categories, excluding voluntary grasp. Infants were considered to have a motor milestone response if they met the following two criteria: improvement in at least one category (i.e. an increase in the score for head control, rolling, sitting, crawling, standing, or walking of ≥ 1 point, an increase in the score for kicking of ≥ 2 points, or achievement of the maximal score for kicking) and more categories with improvement than categories with worsening (i.e. a decrease was defined as ≥ 1 point decrease in the score for head control, rolling, sitting, crawling, standing, or walking and a decrease in the score for kicking was defined as a decrease of ≥ 2 points).<br/> <sup>d</sup> Response was defined as an increase of at least 4 points from baseline in the CHOP INTEND score at the end of trial visit (day 183, 302, or 394).<br/> <sup>e</sup> In case a participant had more than one event, only the event with the highest severity was counted. </p> <p>HINE: Hammersmith Infant Neurological Examination; CHOP INTEND: Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Intrathecally‐injected nusinersen versus sham procedure (Finkel 2017 (ENDEAR))</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/full#CD006281-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006281-tbl-0006"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Diagnostic criteria for SMA type I</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary criteria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age of onset before six months and have never been able to sit independently</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Genetic analysis to confirm the diagnosis, with homozygous deletion or heterozygous mutation of the <i>SMN1</i> gene (5q11.2‐13.3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Supporting criteria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symmetrical muscle weakness of limb and trunk</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proximal muscles more affected than distal muscles and lower limbs more than upper limbs </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No abnormality of sensory function</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum creatine kinase (CK) activity not more than five times the upper limit of normal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denervation on electrophysiological examination, and no nerve conduction velocities below 70% of the lower limit of normal. There are no abnormal sensory nerve action potentials </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Muscle biopsy showing atrophic fibres of both types, hypertrophic fibres of one type (usually type I), and in chronic cases type grouping </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No involvement of the central neurological systems, like hearing or vision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No involvement of non‐neurological organs</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="1"> <div class="table-footnote"> <p><i>SMN1</i> gene ‐ survival motor neurone 1 gene<br/> <a href="./references#CD006281-bbs2-0203" title="ZerresK , DaviesKE . 59th ENMC International Workshop: Spinal Muscular Atrophies: recent progress and revised diagnostic criteria 17‐19 April 1998, Soestduinen, The Netherlands. Neuromuscular Disorders1999;9(4):272‐8. ">Zerres 1999</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Diagnostic criteria for SMA type I</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/information#CD006281-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006281-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Nusinersen versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Acquisition of head control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Acquisition of the ability to sit independently <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Acquisition of the ability to stand <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Acquisition of the ability to roll <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Motor milestone response on the Hammersmith Infant Neurological Examination‐Section 2 (HINE‐2) (final analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Motor milestone response on the Hammersmith Infant Neurological Examination‐Section 2 (HINE‐2) (interim analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Response on the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) (final analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Severe adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Nusinersen versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006281.pub5/references#CD006281-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006281.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006281-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006281-note-0001">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD006281-note-0012">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD006281-note-0011">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006281\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006281\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006281\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006281\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006281\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006281\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006281\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006281\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006281\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006281\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006281\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006281\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006281\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006281\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006281\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006281\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006281\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006281\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WbpyPs9C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006281.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006281.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006281.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006281.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006281.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725045254"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006281.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725045258"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006281.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e71a5bc441bdf',t:'MTc0MDcyNTA0NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 